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Abstract 
G9a is a lysine methyltransferase, which is responsible for mono- and di-
methylation of lysine 9 on histone 3 in euchromatic loci containing transcriptionally 
active genes. G9a has been shown to be implicated in the methylation of lysine 27 on 
histone 3 as well. This study focused on characterizing the interaction between G9a and 
mesoderm induction early response 1 (MIER1), a fibroblast growth factor (FGF)-
activated transcriptional regulator. Glutathione S-transferase pull-down assay showed that 
MIER1 interacts with G9a via the SANT domain, a domain common in MIER1 
isoforms. Co-immunoprecipitations using lysates from human embryonic kidney cells 
(HEK-293) confirmed the validity of the interaction between these two proteins in vivo. 
Co-immunoprecipitations also revealed MIER1 to interact with chromodomain protein, 
Y-like (CDYL). Moreover, CDYL bridges enhancer of zeste homolog 2 (EZH2), the 
methyltransferase subunit of PRC2 complex, to MIER1. Methyltransferase assays using 
histone H3 N-terminal [H3(21-44)] peptide or recombinant histone H3 monomer as 
substrates showed recombinant G9a to have no detectable methylation activity towards 
H3K27. GST-MIER1 does not have intrinsic histone methyltransferase activity and does 
not methylate H3K27. However, the MIER1 complex immunoprecipiated from HEK-
293 cells does methylate H3K27. A methyltransferase associated with MIER1 in HEK-
293 cells, such as G9a or EZH2, could be responsible for this methylation.  
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Chapter 1: Introduction 
 
1.1 General introduction 
1.1.1   Epigenetics 
Epigenetics is a term first coined by the British embryologist Conrad Waddington 
in 1942 in the context of developmental biology. Waddington believed that the 
interactions between networks of genes play an important role in embryonic development. 
His view on development, which he illustrated in “epigenetic landscapes” (Fig. 1), was 
what we now would call differential gene expression and regulation. In his illustrations, 
the developmental system is depicted as a landscape where bifurcating and deepening 
valleys run down from a plateau [1, 2]. In Fig. 1A, the fertilized egg is represented by the 
rippling plateau and the direction the ball rolls signifies the developmental path from the 
egg to a particular tissue or organ at the end of a valley. Moreover, the paths, slopes, and 
the cross-sections of the valleys are under genetic control, which is represented in Fig. 
1B; the pegs represent the genes and the figurative ropes represent the “chemical 
tendencies” of the gene.  Using this figure, Waddington attempted to illustrate that the 
relationship between a gene and its phenotypic effects is not simple because “if any gene 
mutates, altering the tension in a certain set of guy ropes, the result will not depend on 
that gene alone, but on its interactions with all the other guys”[2]. Overall, Waddington 
used the term epigenetics to describe “the branch of biology which studies the causal 
interactions between genes and their products, which bring the phenotype into being”[3]. 
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However, with increased knowledge of chromatin biology, epigenetics has now been 
adapted to a more chromatin centric meaning.  
Epigenetics is currently defined as an alteration in gene expression without 
alterations in DNA sequence. Epigenetics plays a fundamental role in an array of cellular 
functions including development, cell proliferation and differentiation, genomic 
imprinting and X chromosome inactivation. Thus anomalies in epigenetic signaling could 
lead to tumour genesis and other health implications (reviewed in [4]). According to the 
classic model of cancer progression, which was proposed in 1971 by AG Knudson, two 
successive mutations (“hits”) are required to for a normal cell to turn into a tumour cell. 
In other words, two inactivation events are needed to silence the two alleles of a tumour 
suppressor gene [5].  However, recent studies have shown that epigenetic events may also 
be involved in tumour development and progression, which was initially indicated by 
Holliday in 1979 [6]. Epigenetic modulation of gene expression can alter tumour-related 
phenotype, such as invasion, angiogenesis, motility and proliferation [7]. Two most 
notable epigenetic alterations that take place in the mammalian genome and could impact 
tumour genesis are DNA methylation and histone modifications. 
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A.              B. 
  
Figure 1: Waddington’s illustrations 
A) Waddington’s epigenetic landscape. In 1957, Conrad Waddington used an 
epigenetic landscape to depict the decision making involved in the process of cellular 
development.  This visual theory illustrates that the cell (represented by a ball) has 
specific permitted paths to follow, which lead to different outcomes or cell fates 
(reproduced from Waddington, p. 29)[2]. B) The complex system of interactions 
underlying the epigenetic landscape. This diagram depicts the control of the chemical 
tendencies of many genes on the route and the slope of any particular valley (reproduced 
from Waddington, p. 36) [2]. 
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1.1.2   DNA methylation  
DNA methylation is important in genome organization and transcriptional 
repression of unneeded genes in differentiated cells (reviewed in [7]).  DNA methylation 
is catalyzed by DNA methyltransferases (DNMTs), which add a methyl group to the 
carbon 5-position of the cytosine nucleotides adjacent to a guanine (CpG), forming 5-
methyl-2’-deoxycytidine (5-mdC). S-adenosyl-methionine (SAM) is the methyl donor 
(reviewed in [4]). In the genome, CpG di-nucleotides are usually clustered in groups or 
CpG islands at or near the promoters and initial exons of many genes. When these CpG 
di-nucleotides are unmethylated, they enable transcription. DNA methylation serves as a 
stable tag on the promoter of a gene and recruits other proteins such as histone de-
acetylases (HDACs), which form large-scale heterochromatic structures that lead to 
silencing of the associated genes.  
1.1.3   Chromatin structure and histone modifications 
The fundamental unit of a chromatin is the nucleosome, which is comprised of 
two pairs of core histones H2A, H2B, H3 and H4 forming a protein octomer, with 
approximately 146 base pairs of DNA wrapped around it (reviewed in [7, 8]) The core 
histones have a distinct globular fold domain that enables histone-histone and histone-
DNA interaction, forming the nucleosomal disc framework. Moreover, the core histones 
have unstructured N-terminal sequences (“histone tails”) that protrude out of the 
nucleosome disc and are subjected to various post translational modifications (PTMs). 
These PTMs include, but are not limited to, methylation, acetylation, ubiquitination, 
citrullination and phosphorylation (reviewed in [8]). The functional roles of these PTM 
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marks in transcription regulation and the mechanisms by which they modulate chromatin 
remodeling are now intensively studied.  
1.1.4   Histone code hypothesis 
Interplay between different histone PTM marks is evident and these modifications 
have been proposed to serve as regulatory “codes”. This is known as the histone code 
hypothesis, proposed in 2000 by Strahl and Allis, which states that “multiple histone 
modifications, acting in a combinatorial or sequential fashion on one or multiple histone 
tails, specify unique downstream functions” [9]. Information encoded in DNA is in part 
regulated by histone modifications by recruiting other proteins that either “read”, or 
modify the histone tails. The specific chromatin-modifying enzymes includes “writers” 
and “erasers”, the former adds a PTM onto the histone tail, while the latter removes the 
modification. Together, the “readers”, “writers”, and “erasers”, regulate the transcription 
of target genes [8, 10].  
1.1.5   Writers, erasers and readers of the histone code 
Histones are highly basic as they contain a large proportion of the two positively 
charged amino acids: lysine (K) and arginine (R). Therefore, modifications of these lysine 
residues such as acetylation or methylation cause structural alterations in the histone 
protein and thus the nucleosome [11]. Histone acetyltransferases (HATs) are the authors 
of acetylation levels; they write the acetylation mark onto these lysines, while histone 
deacetylases (HDACs) are the erasers that are responsible for removing the acetyl group.  
However, these modulations are significant only when they are relayed by histone code 
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readers [11]. The readers of the histone code include effector domains of proteins which 
bind to a specific epigenetic mark and are responsible for recruiting machinery which 
serve to stabilize or remodel specific chromatin states [12]. These proteins are defined by 
their characteristic reader module including bromodomains, chromodomains, ankyrin 
repeats, tudor, malignant brain tumour (MBT) domain, WD40-repeat and plant 
homeodomain (PHD) finger domains.  Bromodomains recognize and bind to ε-N-
acetylated lysine residues within histone tails, while the remaining modules target 
methylated lysines or arginines in a residue-specific manner [13, 14]. Reading of the 
acetylation marks could lead to further remodeling at the epigenetically modifiable sites, 
ultimately controlling transcriptional activity [11]. When lysines are acetylated, the 
positive charge on the ε-amino group of the side chain is neutralized, which leads to 
increased chromatin accessibility and thus transcriptional activation (reviewed in [15]). 
Similar to acetylation, methylation too has its writers, erasers and readers. Histone 
lysine methyltransferases (HKMTS) and protein arginine methyltransferases (PRMTs) are 
the writers which catalyze the lysine and arginine methylation, respectively. Conversely, 
histone lysine demethylases (HKDMs) remove the methyl group from lysine residues 
contributing to the dynamic methylation regulation [8]. The methylated lysine and 
arginine residues are read by chromodomains, which were first described by Murray in 
1965 [16]. Unlike histone acetylation which neutralizes the positive charge on the lysine, 
no such change in charge is evident with methylation. Since histone methylation does not 
modify the electrostatic interactions between histones and DNA, its significance for 
chromatin structure was undefined for decades (reviewed in [15]). However, it is now 
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evident that the transcriptional significance of histone methylation depends on the 
location of the lysine which is methylated [8]. 
1.1.6   Histone lysine methylation  
Histones contain a high content of lysine residues which can be methylated, 
leading to either transcriptional activation or repression. The methylation sites that have a 
defined biological function include tri-methylated histone 3 lysine 4 (H3K4me3), tri-
methylated histone 3 lysine 9 (H3K9me3), tri-methylated histone 3 lysine 27 
(H3K27me3), tri-methylated histone 3 lysine 36 (H3K36me3), and tri-methylated histone 
4 lysine 20 (H4K20me3). The H3K4me3 epigenetic mark is mostly found in promoter 
regions of actively transcribed genes, whereas the H3K36me3 modification is associated 
with transcription elongation. Moreover, the tri-methylation of H3K9, H3K27, and 
H4K20 are enriched at constitutively condensed chromatin and inactive genes [17]. 
Furthermore, in addition to being tri-methylated, lysines can be mono- and di-methylated, 
which augments the functional diversity of lysine methylation. As mentioned earlier, 
H3K4me3 is exclusive to active genes, however, H3K4me2 is found at both inactive and 
active genes [8]. 
1.1.7   H3K27 methylation 
Lysine 27 on histone 3 can be mono-, di-, and tri-methylated. Tri-methylated 
H3K27 is an epigenetic repressive mark. H3K27me3 plays a role in development such as 
in X chromosome inactivation [18, 19] and parental imprinting [20] and is established by 
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the Polycomb group (PcG) proteins. PcG proteins exist as subunits of multi-protein 
complexes that are responsible for the establishment and maintenance of histone PTMs 
[21]. Polycomb (Pc) protein, the founding member of PcG, was initially identified as a 
repressor of homeotic (Hox) genes in Drosophila. Strong developmental defects, mostly 
homeotic conversions, were evident with loss of Pc function [22, 23].  Further research 
discovered PcG proteins to be a group of genes which, if mutated, causes pheonotype 
reminiscent of Pc; improper body segmentation in Drosophila.  In metazoans, at least 
three distinct multimeric complexes are involved in the PcG silencing pathyway, which 
include the Polycomb Repressive Complex 1 (PRC1), PRC2, and Pleiohomeotic 
Repressive Complex (PHORC) [21]. PRC2 complex is extensively studied and is 
composed of the four core subunits. In Drosophila, the core subunits include Enhancer of 
zeste (E[z]), Suppressor of zeste 12 (Su[z]12), Extra Sex Combs (ESC) and Multicopy 
Suppressor of IRA1 (MSI1) [21]. These four members of the PRC2 complex are named 
differently in metazoans; Enhancer of Zeste Homolog 1/2 (EZH1/2), suppressor of zeste 
12 (SUZ12), embryonic ectoderm development (EED) and retinoblastoma associated 
protein 46/48 (RbAp46/48) [24]. The enhancer of zester homolog 2 (EZH2) protein in the 
PRC2 complex tri-methylates H3 lysine 27 [24]. Genome-wide mapping studies have 
shown members of PRC1 and PRC2 complexes to co-occupy many target loci in 
metazoans. Furthermore, there is biochemical evidence that H3K27me3 serves as a PRC1 
docking site. Together these studies are commonly interpreted as the “PcG paradigm”, 
which proposes that the PRC complexes act sequentially. According to this paradigm, 
PRC2 serves as the “initiation complex” and tri-methylates H3K27, while PRC1 complex 
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acts as the “maintenance complex” which recognizes the mark and subsequently mediates 
downstream H2A monoubiquitination [21, 25]. 
1.1.8   Histone lysine methyltransferases (HKMTs) 
In humans, there are at least 27 histone methyltransferases, most of which are 
substrate specific [26]. All HKMTs, with the exception of disruptor of telomeric 
silencing-1-like (DOT1L) methyltransferase, have an evolutionary conserved Suppressor 
of Variegation 3-9 [SU(VAR)3–9], Enhancer-of-Zeste, Trihorax (SET) domain which 
contains the catalytic site. SUV39H1/2, G9a, GLP, and SETDB1/2 are human SUV39 
proteins that use their SET domain to specifically methylate H3K9 and are related to 
heterochromatic gene silencing. Moreover, they contain domains that recognize 
epigenetic marks; SUV39H1/2 contains chromodomain, which recognizes methylated 
lysine and arginine residues, G9a/GLP have ankyrin repeats domain, which bind mono- 
and di-methylated histone 3 lysine 9 (H3K9) residues, and SETDB1/2 harbours methyl-
CpG-binding domain (MBD). In addition to the SUV39 proteins, there are other HKMTs 
that comprise the EZH family, which are homologous to the PcG protein Enhancer of 
Zeste. EZH proteins methylate H3K27 with their SET domain, and unlike the SUV39 
proteins, they have no Post-SET domain [8]. The Post-SET domain contains three 
conserved cysteine residues that play an important role in the catalytic activity of SUV39 
proteins [27, 28].  
HKMTs transfer a methyl group from the substrate SAM onto the terminal amine 
of the substrate lysine or arginine residues. With the exception of DOT1L, this transfer 
occurs within the SET domain, where the cofactor and peptide substrates are brought in 
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close proximity enabling the SN2 transfer (nucleophilic substitution reaction) of the 
methyl group to occur. This reaction generates S-adenosyl-homocysteine (SAH) and the 
methylated histone side changes as shown in Fig. 2 (reviewed in [29]). 
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Figure 2: S-adenosyl-methionine is the methyl donor in methylation of histone lysine 
residues 
Histone methyltransferases transfer the methyl group from the s-adenosyl-
methionine (SAM) cofactor onto the lysine amino group of the substrate histone via an 
SN2 reaction. The reaction results in the formation of an N-methylated lysine and s-
adenosyl-homocysteine (SAH). Figure adapted by permission from Macmillan Publishers 
Ltd: Nature Publishing Group, 2013 [29]. 
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1.1.9   Recruitment of histone methyltransferases to their genomic destination 
Recruitment of histone methyltransferases to specific histone targets is an 
important focus area and extensive research is conducted to answer the “how” and 
“when” of this phenomenon. Several histone-modifying enzymes are now shown to be 
recruited by specific DNA sequences, examples of which include the Drosophila 
melanogaster Trithorax group (TrxG) response elements (TREs) and the Polycomb group 
(PcG) reponse elements (PREs), which recruit TRX (a H3K4 methyltransferase) and PcG 
proteins [the polycome repressive complex 2 (PRC2) complex containing EZH2, a 
H3K27 methyltransferase], respectively. TrxG is a heterogeneous collection of proteins 
that function antagonistically against the PcG to activate target gene expression (reviewed 
in [30]). Specific DNA-binding transcription factors recognize the TREs and PREs, and 
thus enable them to recruit these methyltransferases. A DNA sequence that enhances PcG 
binding is evident in human cells as well, demonstrating similarities to D. melanogaster 
PREs and suggesting that there is some conservation in the PcG recruitment mechanism.  
In addition to specific DNA sequences directing methyltransferases to their 
histone targets, long non-coding RNAs (lncRNAs) have also been proposed to have a 
recruiting role. Members of the PRC2 complex, the methyltransferase G9a and the 
methyltransferase complex member WD repeat domain 5 (WDR5), are some of the 
proteins that bind to lncRNAs (reviewed in [31]). Additionally, certain lncRNAs are able 
to regulate multiple methyl marks. For example, the recruitment of the PRC2 complex 
containing the H3K27 methyltransferase and a complex containing the H3K4 
demethylase KDM1A are coordinated by the human lncRNA HOTAIR to efficiently 
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repress specific loci (reviewed in [31]). lncRNAs may play a vast role in the specific 
targeting of the methyl-modifying proteins as there are 6736 lncRNAs in the human 
genome and can be both in cis or trans configuration which further increases the diversity 
of lncRNAs [32]. However, additional research is required to elucidate the mechanisms.  
Small non-coding RNAs also have a role in orchestrating histone methylation and 
other chromatin modifications. In Schizosaccharomycs pombe, for instance, the 
establishment and maintenance of centromeric heterochromatin characterized by H3K9 
methylation, requires the RNA interference (RNAi) machinery (reviewed in [31]). This is 
conserved in evolution to some degree, as it is also evident in Arabidopisis thaliana [33] 
and in mammals [34]. In addition to H3K9 methylation, H3K27 tri-methylation and 
heterochromatin changes during X-chromosome inactivation in mice are also induced by 
the RNAi machinery [35].  
Histone methylation is also directed by DNA methylation. Some examples include 
the A. thaliana H3K9 methyltransferases SUVH4 and SUVH5 which are Set- or Ring-
associated (SRA) proteins that bind to methylated DNA and also have the catalytic SET 
domain required for histone methylation. Mutation in the SRA domain results in 
significant attenuation in binding to methylated DNA in vitro, and reduction in DNA 
methylation and H3K9 di-methylation in vivo. This suggests that SRA domain plays a 
role in the recruitment and maintenance of the SUVH4 to silenced loci [36, 37].  
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1.2   Euchromatic human methyltransferase 2 (G9a) 
1.2.1   G9a  
G9a, also known as euchromatic histone methyltransferase 2 (EHMT2), was first 
identified in 2001 by Tachibana et al. [38], as a novel mammalian lysine-preferring 
HMTase.  G9a methylates the lysine residues of histone H3 like SUV39, the first 
identified lysine-preferring HMTase, but with a 10-20 fold increased activity. In addition, 
compared with the SUV39 proteins which methylate only H3K9, G9a methylates H3K9 
and to a lesser degree, H3K27 [38]. Moreover, while SUV39 proteins tri-methylate H3K9 
specifically at the percentric heterchromatic region, G9a is responsible for mono- and di-
methylation of lysine 9 on the euchromatic loci involved with transcriptionally active 
genes [39]. Also, G9a methylates histone H1.4, and  non-histone proteins, including p53 
(K373) [41], WIZ (K305) [42], CDYL1 (K135) [40, 42], ACINUS (K654) [42], Reptin 
(K67) [43], and itself at K165 [40]. G9a auto-methylation plays a role in G9a-HP1 
interaction [40, 44]. The biological significance of the methylation of these non-histone 
proteins remains to be elucidated.  
1.2.3   G9a structure 
G9a exists as a heteromeric complex with the highly similar methyltransferase 
G9a-like protein [GLP, also known as euchromatic histone methyltranseferase 1 
(EHMT1)]. Mono- and di-methylation of H3K9 is greatly attenuated when either G9a or 
GLP methyltransferase activity is diminished [45].  Double knockout of G9a and GLP 
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does not augment the reduction in H3K9me1 and H3K9me2 levels [46]. Thus, the loss of 
GLP activity in vivo generally cannot be compensated by G9a, and vice versa.  
G9a consists of an N-terminal auto-methylation site, a glutamic acid-rich (E-rich) 
domain, a cysteine-rich (Cys-rich) domain, ankyrin repeats and a SET domain [47] (Fig. 
3). The N-terminal of G9a contains an auto-methylation site, at lysine 165, which can be 
di-methylated [40]. Methylated G9a binds and recruits histone protein 1 (HP1) [40, 44]. 
The E-rich region of G9a composed of 24 contiguous glutamic acid residues (300-323aa) 
[47] is similar to the poly-acidic regions present in nuclear protein nucleolin [48], the 
non-histone chromosomal high mobility group 1 (HMG1) protein [49] and the major 
centromere auto-antigen CENP-B [50, 51]. The Cys-rich region of G9a contains 12 
cysteine residues. The Cys-rich region acts as a binding site for neuron-restrictive 
silencing factor (NRSF), via which G9a is involved in repression of neuronal genes in 
non-neuronal tissues [52].         
The ankyrin repeats of G9a (649-879aa) are shown to be involved in epigenetic 
mark recognition. They bind to mono- and di-methylated lysines and their specificity is 
comparable to that of other methyl binding protein modules including chromodomains, 
tudor domains and PHD fingers. Ankyrin repeats are helix-turn-helix--turn structures 
with the helices stacked and the -turns projected out at right angles. The -turns and the 
helices of the fourth and fifth repeats sandwich the H3 peptide, while a partial 
hydrophobic cage formed by three tryptophans (Trp839, Trp844 and Trp877) and one 
acidic residue (Glu847) recognize and bind the di-methylated lysine (H3K9me2) 
epigenetic tag. The methyl groups of H3K9me2 project towards the hydrophobic 
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tryptophans while the proton of the N atom of the lysine bridges to the acidic Glu847, 
and thus mutations in these G9a residues attenuate peptide binding. This hydrophobic 
pocket binds H3K9me1 and me2 with equal affinity; however, it does not bind H3K9me3 
due to steric hindrance [53]. 
The SET domain is conserved among histone methyltransferases and contains the 
catalytic methyltransferase activity. The SET domain (1038-1155aa) has a pseudo-knot-
type structure comprised of asheet fold separated by an -helical iSET motif [54, 55]. 
It contains a central channel which binds SAM and the protein substrate on opposite sides 
of the domain. The methyl group of SAM is positioned at the base of the channel, while 
the side chain of the target lysine protrudes into the channel from the other end. The 
substrates within the channel are held in position via hydrogen bonding which allows the 
methyl group from SAM to be transferred onto the lysine -amine by a SN2 reaction [56, 
57]. 
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Figure 3: Domain structure of G9a  
G9a consist of an N-terminal automethylation site (K165), E-rich domain made of 
24 contiguous glutamic acid residues, Cys-rich domain comprised of 12 cysteine residues, 
the product-binding ankyrin repeats and the catalytic SET domain. Adapted by 
permission from Oxford University Press: Nucleic Acids Research, 2010 [45]. 
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1.2.4   The effect of other post-translational modifications on G9a activity 
G9a methylation is not dependent on pre-existing epigenetic marks like some 
other HKMTs including SET1 or DOT1 [58]. The absence of the epigenetic marks on the 
target lysine or adjacent residues is sufficient for G9a to transfer the methyl group. G9a 
interacts with H3 at amino acids 6-11, with a seven amino acid heptapeptide RK/ARK 
consensus, such as 6-TARKSTG-12 of H3, being the minimum substrate recognition 
criterion in vitro [59]. When H3K9 is acetylated, or when H3S10 or H3T11 are 
phosphorylated, H3K9 methylation is blocked. H3K4 acetylation or methylation, on the 
other hand, reduces H3K9 methylation. Moreover, H3R8 methylation blocks H3K9 
methylation [42, 59]. Phosphorylation of H3S10 also blocks product binding [53].  
1.2.5   Recruiting other proteins to reinforce silencing 
G9a acts as a chromatin-compacting gatekeeper and this role is further reinforced 
by its ability to recruit other proteins to chromatin. These proteins include histone H1.4 
[60], heterochromatin protein 1 (HP1) [40, 44] and CCAAT/ Enhancer-binding protein- 
(C/EBP-) [61]. Histone H1 has 11 variants in human cells, all of which are generally 
silencing and play a role in establishing higher order chromatin structure. Nucleosome 
repositioning and sliding is blocked by H1 arrangement. H1 positioning also prevents 
DNA accessibility to other proteins (reviewed in [45, 62]). H1.4 of the H1 variants 
contributes to dynamic, gene specific silencing [60]. G9a methylates H1.4 at lysine 26 
(H1.4K26) and plays a direct role in recruiting H1.4 to chromatin [60]. H1 methylation 
further reinforces silencing as it acts as another epigenetic mark to recruit HP1 [60, 63], 
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L3MBTL1, which participates in chromatin compaction [60, 64] and MSX1, a homeobox 
transcriptional repressor [65]. 
G9a and GLP are essential in recruiting HP1 to euchromatin. When the activity of 
either G9a or GLP is attenuated, HP1 recruitment to euchromatin binding is diminished; 
HP1 occupancy at specific promoters is reduced with loss of G9a [46, 66, 67]. G9a 
recruits HP1 by auto-methylating, possibly at multiple sites [40, 44]. The dominant auto-
methylation site (K165) of G9a resembles the region surrounding H3K9. There is even a 
phosphorylation site that diminishes HP1 binding.  When the target lysine (K165)is 
mutated, the HP1 binding is eliminated and it delocalizes from G9a-containing loci. In 
addition to binding to the auto-methylated G9a methyltransferase, HP1 binds specifically 
to di-methylated and tri-methylated H3K9 by its N-terminal chromodomain (reviewed 
in[68]). HP1 recruits other proteins and DNA methyltransferases (DNMTs) not only in 
the formation of silent heterochromatin but also euchromatin (reviewed in [69]). A direct 
interaction between G9a and the DNA methyltransferases has been proposed by some 
studies [70, 71]. Nonetheless, HP1 binding to auto-methylated G9a or H3K9me2/me3 
could play a role in recruiting the DNA methyltransferases DNMT3a and DNMT3b. 
Certainly, DNMT3a, DNMT3b and CpG methylation is attenuated in the absence of HP1 
or G9a, while HP1 knockdown has little effect on G9a binding at the TNF promoter. 
This indicates that G9a is the main player of silencing at that promoter, while HP1 acts as 
a bridge serving to recruit DNMTs [67]. 
In addition, studies have shown G9a to bind and methylate CCAAT/Enhancer-
binding protein- (C/EBP-). C/EBP- methylation blocks its ability to activate 
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transcription [61]. When the catalytic SET domain of G9a is not present, the binding is 
not observed. This suggests product binding is the active mechanism, but this possibility 
has not been formally tested [61]. Overall, G9a interacts with other proteins and recruits 
them to target genes to reinforce silencing. 
1.2.6   The role of G9a: biological relevance  
Multiple biological roles for G9a have been proposed since it is ubiquitously 
expressed and functions as the major euchromatic H3K9me1 and H3K9me2 histone 
methyltransferase (HKMT). G9a is essential in mouse development; G9a knockout results 
in embryonic lethality around embryonic day 9.5 (E9.5) due to severe growth defects [46, 
72]. This is further supported by the fact that mutant mice with catalytically inactive G9a 
HKMT also have embryonic lethal phenotype, as seen in the G9a knockout mice 
(reviewed in [73]). When G9a is knocked out in cells, DNA methylation and HP1 binding 
to euchromatin is diminished, which results in loss of silencing [72]. In addition, 
differentiation of ES cells in absence of G9a leads to apoptosis [72]. Together, these data 
suggest that H3K9 methylation by G9a is important for mouse development. 
Furthermore, developmental defects of germ cells and lack of meiosis completion 
in either sex is seen in germ lineage-specific G9a knockout [74]. When G9a is 
specifically knocked out in lymphocytes, lymphocyte development is scarcely affected, 
with some impairment in the immune responses. A reduced usage of Ig L chains and a 
diminished Ig gene assembly in bone marrow precursor cells is evident in B-cell-
specific G9a knockout mice. B cells deficient in G9a do not respond well to LPS + IL-4 
in vitro [75]. T-cell-specific G9a knockout mice have normal T-cell development in the 
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thymus; however there is impaired expression of lineage-specific Th2-associated cytokine 
genes such as IL-4, IL-5, and IL-3. Thus, the mice are unable to defend themselves 
against parasitic infections [76].  
Neuron-specific G9a knockout mice have interesting postnatal and forebrain 
phenotypes [77]. These mice have multiple non-adult neuronal genes de-repressed in the 
forebrain but with no apparent neuronal developmental or architectural defects. 
Nonetheless, various abnormal phenotypes, especially defects in cognition and adaptive 
behaviour, are evident in these mice.  G9a has a similar role in neuronal function in 
Drosophila, where G9a deficiency results in learning and memory defects [78].  
Furthermore, G9a-mediated H3K9me2 methylation has been reported to play a critical 
role in cocaine-induced neuronal responses.  Alterations in gene expression in the nucleus 
accumbens (NAc) neurons in mice is seen with repeated cocaine exposure. These 
alterations are critical for cocaine-induced changes in neural morphology and behaviour 
that may be responsible for cocaine addiction. One of the changes that occur with 
repeated cocaine exposure in mice is the reduced expression levels of G9a and GLP 
specifically in the NAc neurons, leading to reduced H3K9me2 levels. This attenuation in 
H3K9me2 levels subsequently causes up-regulation of G9a-repressed genes. G9a (G9a-
GLP complex) or the methyltransferase activity of G9a may be a novel target for 
regulating cocaine addiction if these molecular mechanisms in mice can be generalised to 
cocaine addiction in humans [79].   
Additionally, G9a is required for the silencing of the homeobox gene Oct3/4, 
which in turn is important for pluripotency [66]. It is also important in NRSF/REST-
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mediated silencing of neuronal genes in non-neuronal lineages [52], PRDI-BF1 silencing 
in B-cell differentiation [80] and CDP/cut mediated silencing of genes essential in cell 
differentiation and proliferation [81]. 
Given the role of G9a in various processes, including cell differentiation and 
proliferation [81], it is not surprising that vicissitudes in G9a expression level are seen in 
many cancers. The expression of G9a is up-regulated in many tumors including 
hepatocellular, colon, prostate, lung and invasive transitional cell carcinomas and in B 
cell chronic lymphocytic leukemia [41]. In bladder and lung cancer cells, growth 
suppression and apoptosis with an increase in sub-G1 population are seen with G9a 
knockdown [82].  High levels of G9a correlate with poor prognosis in aggressive lung 
cancer, with augmented in vitro cell migration and invasion, and in vivo metastasis. The 
increased metastasis that is evident in lung cancer is due to G9a repression of the 
epithelial cell adhesion molecule, Ep-CAM [83]. In addition, G9a promotes EMT by 
repression of E-cadherin expression in Claudin-low breast cancer (CLBC), which is 
associated with early metastasis [84]. G9a knockdown de-repressed E-cadherin 
expression, preventing cell migration and invasion in vitro, and attenuated tumour growth 
and metastasis in CLBC metastasis models [84].   
1.2.7   G9a inhibitors 
Numerous inhibitors have been developed through structure-based design, 
targeting the catalytic domains of lysine methyltransferases. The two potential sites for 
inhibition include the SAM cofactor binding site and the protein substrate binding cleft. 
Sinefugin, chaetocin, and SAH are some of the natural products that act as competitive 
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inhibitors of SAM. Sinefungin and SAH are not KMT-specific and are structurally similar 
to SAM, while chaetocin’s specificity remains questionable. Chaetocin was first 
described to be a selective inhibitor of Drosphila SU(VAR)3-9, a homologue of human 
SUV39H1; however, recent studies have shown this specificity to be diminished in 
certain in vitro methylation assays (reviewed in [57]). The second class of inhibitors that 
act on the protein substrate binding cleft of lysine methyltransferases include BIX-01294 
and UNC0224. BIX-01294 was among the first of this type of inhibitor to be designed 
and it is a specific G9a and GLP inhibitor (reviewed in [57]). BIX-01294 reduces the 
levels of H3K9me2 in cells and also promotes stem-cell reprogramming with similar 
efficacy as the viral transduction of pluripotency-inducing transcription factors [85]. BIX-
01294 binds the substrate binding cleft in similar manner as observed in the histone H3 
peptide complex, forming similar hydrogen bonds and van der Waals contacts. The 
quinazoline ring of BIX-01294 binds in a region analogous to that bound by the backbone 
atoms of residues T6-R8 and the side chain of R8 in histone H3 peptide.  The R8 residue 
is critical for G9a activity and BIX-01294’s similar conformation as the R8 residue 
enables it to efficiently inhibit the methyltransferase [42]. Moreover, the diazepane ring 
of BIX-01294 also binds to the same location as the side chain of K4, and the benzene 
and piperidine groups occupy similar positions of residues Q5 and T6, respecitively, 
further enhancing the binding affinity of the inhibitor [42]. 
Derivatives of the quinazoline scaffold of BIX-01294 were made by Liu et al. to 
develop the more potent G9a inhibitor UNC0224 with a Kd value of 23 nM, which has 
approximately fivefold greater affinity than that of BIX-01294, which has a Kd value of 
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130 nM [86].  Recently, further optimizations to UNC0224 have been made, yielding 
even more efficient inhibitors with at least sevenfold potency compared to BIX-01294 
[87]. These inhibitors are useful in studying the role of G9a and also illustrate the 
possibility of such structure-based inhibitor design for other oncogenic SET-domain 
lysine methyltransferases such as EZH2 and SMYD3 [57]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 25 
 
1.3   Chromodomain, Y-like: CDYL 
 
1.31   CDYL    
A group of very closely related genes on the human Y chromosome named 
ChromoDomain Y(CDY), was discovered in 1997 by Lahn et al. [88]. In 1999, Lahn et al. 
[89] identified an autosomal homolog of CDY, CDYL (CDY Like) in humans, and Cdyl in 
mice. Human CDYL and CDY are paralogs, and their protein products share 63 % 
identity. On the other hand, human CDYL and mouse Cdyl are orthologs, having protein 
products that share 93 % identity. Using comparative evolutionary studies, Lahn et al. 
(1999), showed that CDY genes are a result of retroposition of CDYL mRNA and 
amplication of the retroposed gene on the Y. Mice do not have CDY on the Y 
chromosome. Instead, mice have two autosomal Cdyl gene transcripts, a highly abundant 
testis specific 2.8 Kb transcript and a ubiquitous 3.6 Kb transcript [89]. The mouse Cdyl 
has been implicated in spermatogenesis. It is abundantly expressed in elongating 
spermatids during histone hyperacetylation and replacement. In humans, CDY gene 
encodes the chromodomain Y protein, which is specifically expressed in the testes, 
whereas CDYL expresses the ubiquitous CDYL transcript [89].  
1.3.2   CDYL domains and function  
Both CDY and CDYL contain a canonical chromodomain in their N-terminal 
region and domain with significant sequence homology to the enoyl-coenzyme A 
hydratase/isomerase catalytic domain near the C-terminal region [89]. The mouse Cdyl 
recruits HDAC1 and HDAC2 and binds to coenzyme A (CoA) via its putative catalytic 
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domain [90]. However, HDAC recruitment represses the catalytic domain’s ability to 
bind CoA. Thus, Cdyl interacts with CoA only in the absence of HDACs. Caron et al. 
(2003) [90] found that the cellular content of HDAC1 and HDAC2 decreases significantly 
in mouse spermiogenesis, while Cdyl levels do not. This decrease in HDAC1 and 
HDAC2 levels would enable Cdyl to bind CoA. In 2002, Lahn et al. [91] claimed 
recombinant Cdyl to have in vitro HAT activity, and they suggested Cdyl to play a role in 
histone acetylation during spermiogenesis. However, Caron et al. (2003) [90] were not 
able to detect any significant HAT activity associated with recombinant Cdyl. Thus, the 
role of Cdyl in histone acetylation during elongation of spermatids remains unclear.  
CDYL has been identified to be a component of repressor complexes C-terminal 
binding protein (CtBP) [92] and REST/CDYL/G9a [93], where CDYL bridges G9a to the 
transcription repressor RE1-binding silencer of transcription (REST). Mulligan et al. 
(2008) [93] showed CDYL to also interact with mesoderm early response 1 (MIER1), 
HDAC1 and HDAC2. Since CDYL is part of such repressor complexes, CDYL has been 
suggested to mainly function as a transcription corepressor in somatic cells [90, 94, 95]. 
CDYL contains a chromodomain near its N-terminus, which generally recognizes 
methylated histone lysine residues [89]. CDYL specifically interacts with the repressive 
H3 lysine methylation marks, H3K9me3, H3K27me2 and H3K27me3, via its 
chromodomain. CDYL does not bind H3K4 methylation modifications which are 
associated with transcriptional activation [96]. Furthermore, CDYL interacts with PRC2 
complex proteins, SUZ12, EED and EZH2 in vivo [96]. CDYL directly interacts with 
EZH2 and increases the activity of EZH2 towards oligonucleosome substrates. Genome-
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wide analysis showed CDYL to share a significant number of common genomic targets 
with EZH2. However, CDYL does not bind to classical PRC2 target promoters such as 
those of the HoxA family genes [96]. HoxA is one of the four clusters of Hox family 
genes (reviewed in [97]). Even though Zhang et al. (2011) [96] showed CDYL to interact 
with EZH2, previous biochemical purification approaches did not show CDYL to be in a 
complex with the PRC2 complex [98]. Thus, it is possible that CDYL is a peripheral 
component of the PRC2 complex. Further research is required to determine the precise 
role of CDYL in the biological functions of PRC2 complex and H3K27 methylation.  
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1.4   Mesoderm induction early response 1: MIER1 
1.4.1   MIER1 
 Mesoderm induction early response 1 (MIER1) is a fibroblast growth factor 
(FGF)-activated transcriptional regulator originally identified in Xenopus laevis [99]. It is 
highly conserved in evolution, with 95 % identity between human and mouse sequences 
at the amino acid level.  The mier1 gene spans 63 Kb and consists of 17 exons. It 
produces six protein isoforms with different amino and carboxyl termini [100], which 
have a very low or undetectable expression in healthy adult tissues [100, 101].  However, 
there is high expression of these isoforms in human breast carcinoma cell lines and breast 
tumours [100]. Moreover, MIER1 expression pattern analysis using breast samples from 
patients showed a dramatic shift in the subcellular localization in ductal epithelial cells. A 
shift from nuclear to cytoplasmic localization was evident during progression to invasive 
carcinoma [102].  Thus, regulating nuclear levels of MIER1 may play an important role 
in the development of invasive breast cancer.  
1.4.2   MIER1 structure and function 
 The mier1 gene encodes multiple distinct MIER1 proteins through exon skipping, 
facultative intron usage, alternative polyadenylation sites and the use of two alternate 
promoters, P1 and P2 [101]. The MIER1 proteins have common internal region, but 
distinct amino (N-) and carboxy (C-) terminal sequences. Thus far in humans, MIER1 
isoforms with three different N- and two different C- termini have been characterized. 
The N-terminal isoforms result from the use of the two alternate promoters and 
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alternative splicing [101]. Even though P1 and P2 transcription results in mRNAs with 
distinct 5’UTRs, with the exception of the first two amino acids after the start methionine, 
the resulting protein sequences (named N2 and N3 in GenBank) are identical. 
Transcription only from the P1 promoter allows for alternative inclusion of a cassette 
exon, exon 3A. When this exon is included, it transcribes the third N-terminal isoform 
(named N1 in GenBank) with additional sequence at its N-terminus containing a bona 
fide nuclear export signal (NES) [103]. 
The two C-termini isoforms,  and , are produced by the alternate use of a 
facultative intron at the 3’end and differ significantly in size and sequence. As 
demonstrated by PCR analysis, the  isoform is more widely expressed and abundant than 
the  isoform [101]. MIER1 C terminus results from the removal of the facultative 
intron during RNA processing and contains 23 amino acids (aa). The  C terminus 
includes the LXXLL motif, which is essential for interaction with nuclear hormone 
receptors [101, 104]. MIER1 interacts with ER in MCF7 cells and MIER1 
overexpression inhibits estrogen-stimulated anchorage-independent growth [102]. The 
MIER1 C terminus results from inclusion of the facultative intron and consists of 102 
aa, including the functional nuclear localization signal (NLS) [101]. The two isoforms’ 
distinct C termini amino acid sequences suggest different functions.  
MIER1 isoforms have a number of structurally similar features as do other 
transcriptional regulators. These include the acid activation domain, an ELM2 domain, 
and a SANT domain, as shown in Fig. 4 [99]. The ELM2 (EGL-27 and MTA1 homology) 
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domain was initially defined in Egl-27, a Caenorhabditis elegans protein that has an 
important role in patterning during embryonic development [105]. The ELM2 domain is 
evolutionarily conserved. In MIER1, the ELM2 domain serves to recruit histone 
deacetylase 1 (HDAC1) and repress transcription [106]. In addition, MIER1 binds to 
CREB-binding protein (CBP), inhibiting its histone acetyltransferase (HAT) activity. The 
N-terminal region of MIER1, including both the acidic and ELM2 domains, is responsible 
for this interaction [107].  
The SANT domain was first identified in the transcription factors SWI3, ADA2, 
N-CoR and TFIIIB, which gave the acronym “SANT” [108]. The SANT domain is found 
in other proteins as well, including the transcriptional regulatory molecules involved in 
nuclear hormone activity, N-CoR [108] and SMRT [109], the components of 
transcriptional chromatin-regulatory complexes, MTA-1 [110] and MTA-2 [111] and the 
proteins essential for regulating developmental events, Egl-27 [105] and CoREST [112].  
In addition to being implicated in DNA binding, the SANT domain has been shown to be 
involved in protein-protein interactions [108]. It has been shown to interact with 
complexes containing histone deacetylase (HDAC) [112, 113] and histone 
acetyltransferase (HAT) [114]. Nonetheless, the precise role of the SANT domain in 
individual proteins is unknown. In MIER1, the SANT domain interacts with Sp1, and 
dissociates it from its binding sites in the promoter of regulated genes, including MIER1’s 
own promoter and interfering with transcription [115]. There is an implied structural 
and/or functional relationship between the SANT and the ELM2 domain since most 
ELM2-domain containing proteins also have a SANT motif [103]. Furthermore, MIER1 
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interacts with G9a, a histone methyltransferase [116], but the effect MIER1 has on this 
chromatin modifying enzyme is unknown. Overall, both isoforms of MIER1 can function 
as transcriptional regulators by their interaction with chromatin modifying enzymes.  
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Figure 4: Domain structure of MIER1  
MIER1 has two major isoforms, MIER1 and MIER. These two C-termini 
isoforms are produced by the alternate use of a facultative intron 16 at the 3’end; MIER 
C terminus results from the inclusion of this facultative intron. MIER1 C-terminus 
contains a classic LXXLL motif for interaction with nuclear receptors, and MIER1 C-
terminus contains a nuclear localization signal (NLS). Two alternative promoters, P1 and 
P2, result in distinct MIER1 transcripts as well. Transcription from the P1 promoter 
produces MIER1 isoforms that either begin with M-L- or 
MFMFNWFTDCLWTLFLSNYQ- (sequence encoded by exon 3A). Transcription from 
the P2 promoter produces MIER1 isoforms that begin with MAE-. All MIER1 isoforms 
share a common set of domains; the acidic domain, SANT domain, and the ELM-2 
domain, as shown above. 
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1.5   Hypothesis and objectives 
MIER1 has been shown to interact with chromatin modifying enzymes and to 
potentially act as a transcriptional regulator. There has also been recent evidence 
illustrating the role of MIER1 in specifically recognizing and binding to acetylated 
H3K27 (Paterno, unpublished data). Furthermore, MIER1 interacts with HDAC and 
recent experiments have shown MIER1 to augment HDAC activity towards acetylated 
H3K27, removing the acetyl group from lysine 27 (Paterno, unpublished data). Moreover, 
MIER1 has been shown to interact with G9a, a histone methyltransferase [116]. However, 
the MIER1-G9a interaction has been only weakly examined. Taking these together, the 
purpose of this study was to investigate the interaction between G9a and MIER1 
and to determine their role in H3K27 methylation. We hypothesize MIER1 interacts 
with G9a directly, and we also hypothesize MIER1 complexes with a 
methyltransferase to methylate H3K27 (Fig. 5).  
 
Objective 1: Determination of a possible direct interaction between MIER1 and G9a 
GST pull-down assay will be performed between GST-MIERl and various GST-
MIER1 deletion constructs, and recombinant G9a to determine the possibility of an 
interaction between G9a and MIER1 in vitro.  
Objective 2: Characterization of the in vivo interaction between MIER1 and G9a  
Human embryonic kidney cells (HEK-293) will be transfected with MIERl and 
various constructs of G9a, and coimmunoprecipitations will be conducted in order to 
determine whether MIER1 interacts with G9a in vivo. 
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Objective 3: Determination of possible interaction between MIER1, G9a and CDYL 
Human embryonic kidney cells (HEK-293) will be transfected with MIERl, G9a, 
and CDYL, and co-immunoprecipitations will be conducted in order to determine 
whether they exist as a complex in vivo. 
Objective 4: Determination of possible interaction between MIER1 and EZH2 in the 
presence or absence of CDYL 
Human embryonic kidney cells (HEK-293) will be transfected with MIERl and 
CDYL, and co-immunoprecipitation will be conducted in order to determine whether 
MIER1 interacts with EZH2 in the presence of CDYL. 
Objective 5: Determination of possible H3K27 methylation by recombinant G9a  
 The activity of recombinant SET domain and full length G9a towards H3K27 
methylation will be tested with and without the addition of inhibitors (SAM and BIX-
01294), and detected using the streptavidin coated plates and ELISA approach, along with 
Western Blotting.  
Objective 6: Determination of GST-MIER1 methylation activity on H3K27. 
The activity of GST protein and GST fused MIER1 protein towards H3K27 
methylation will be tested with and without the addition of inhibitors (SAM and BIX-
01294), and detected using the streptavidin coated plates and ELISA approach, along with 
Western Blotting. 
Objective 7: Determination of H3K27 methylation by MIER1 complex  
Human embryonic kidney cells (HEK-293) will be transfected with myc-
MIER1, and immunoprecipitation will be conducted in order to pull down transiently 
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expressed protein, along with its in vivo binding partners. The proteins will then be used 
in the methylation assay, and the methylation activity will be detected using streptavidin 
coated plates and ELISA approach. 
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Figure 5: Hypothesised role of MIER1 in H3K27 methylation 
MIER1 acts as a transcriptional regulator by interacting with chromatin modifying 
enzymes such as HKMTs and HDACs. Recent evidence has shown MIER1 to specifically 
bind to acetylated H3K27 (Paterno, unpublished data). A. MIER1 augments HDAC1 
activity towards acetylated H3K27, removing the acetyl group from lysine 27 (Paterno, 
unpublished data) and subsequently enabling H3K27 to be methylated. B. MIER1 
complexes with G9a and/or another putative HKMT and methylates H3K27. 
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Chapter 2: Materials and Methods 
 
2.1   Plasmids 
A. GST-MIER1, GST-aa1-283, GST-aa287-512, GST-aa287-357 
MIER1 (GenBank: AAM97503.1) and its deletion constructs were cloned by 
Zhihu Ding into the pGEX-4T-1 plasmid (a kind gift from Dr. A. Pater, Memorial 
University), which contains the GST-tag, at the EcoRI restriction site [115]. 
B. GST-SANT mutant 
 GST-MIER1 with three point mutations at amino acids 326FYY⇾AAA was 
constructed by Julia Ferguson using QuikChange II XL site-directed mutagenesis kit 
(Strategene 200521).  
C. pCS3+MT, myc-MIER1  
pCS3+MT is a myc-tagged empty vector, which was a gift from Drs. David 
Turner and Ralph Rupp (University of Michigan). Corinne Mercer cloned MIER1 
(GenBank: AAM97500.1) into this vector at the BglII restriction site, making myc-tagged 
MIER1  
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D. myc-G9a-SET 
Myc-G9a-SET was cloned into pCS3+MT vector between EcoR1 and Not1 
restriction sites from EHMT2/pET28a-LIC plasmid (Addgene 25503), via PCR cloning. 
EHMT2/pET28a-LIC plasmid was used to clone the SET domain into pCS3+MT vector. 
The EHMT2/pET28a-LIC plasmid purchased from Addgene was a bacterial expression 
with resistance to kanamycin. It was plated on kanamycin plate and incubated overnight 
at 37 °C. A bacterial colony was picked and grown overnight at 37 °C in 250 ml of 
lysogeny broth (LB) with kanamycin (50g/ml) on a shaker. The plasmid was prepared 
using the Endotoxin-Free Maxi Plasmid Kit (Qiagen 12362).  
PCR amplication of SET domain from the pET28a-LIC plasmid 
PCR was performed on the EHMT2/pET28a-LIC plasmid using G9a-SET 
primers, G9a-SET Forward primer (5’ GCACCATGGGCAGCCATCATC 3’) and G9a-
SET Reverse primer (5’ GTGAATTCTCAAAACCCTAGCTCCTCCC 3’), as listed in 
Table 1. PCR reagents and setting used are shown in Tables 2 and 3, respectively. The 
PCR reagents were mixed and the PCR was performed to amplify the SET domain. The 
PCR product (2 µl) was run on a 1.2 % agarose gel with SYBR Safe DNA Gel Stain (1 in 
10,000 dilution) (10,000X, Invitrogen S33102) to verify the presence of the amplified 
SET domain. After amplification with Platinum Taq DNA polymerase High Fidelity, the 
addition of 3’A-overhangs was performed. The vial was placed on ice and 1 unit of Taq 
DNA polymerase (0.2 µl) was added to the PCR product. It was mixed and incubated at 
72 °C for 10 min. It was then placed on ice and used immediately in the TOPO TA 
cloning reaction as follows using the TOPO TA Cloning Kit (Invitrogen 45-0641): the 
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reagents – 4 µl of PCR product, 1 µl of salt solution (1.2 M NaCl; 0.06 M MgCl2), 1 µl 
of TOPO vector and 5 µl of dH20 – were gently mixed and incubated for 5 min at room 
temperature and then placed on ice.  
Following the TOPO TA cloning reaction, One Shot Mach1-T1R competent cells 
(Invitrogen 45-0641) were transformed. TOPO TA cloning reaction product (2 μl) was 
added into a 1.7 ml sterile tube containing One Shot chemically competent cells and 
mixed gently. It was then incubated on ice for 30 min. The cells were then heat shocked 
for 30 sec at 42 °C and were then immediately transferred on ice. Room temperature LB 
medium (250 μl) was added to the cells and incubated at 37 °C for 1 hr on a shaker. The 
transformation (100 μl) was spread on a pre-warmed agarose plate with ampicillin 
selection and incubated overnight at 37 °C. Thirteen colonies were selected the following 
day and a PCR was performed using “G9a-SET Forward” and “G9a-SET Reverse” 
primers listed in table 1 to check for the presence of the SET domain in the TOPO vector. 
The reagents and setting used for PCR analysis are shown in Tables 4 and 5, respectively. 
The PCR products were run on 1.2 % agarose gel with SYBR Safe DNA Gel Stain (1 in 
10,000 dilution) (10,000X, Invitrogen S33102) to visualise the products. Colony 
containing the SET domain/Topo vector was grown in 6 ml of LB with ampicillin (Amp) 
overnight at 37 °C. Miniprep was performed on the culture using the Promega Miniprep 
Kit (A1460), following the manufacturer’s protocol. Nanodrop Spectrometry (Thermo 
Scientific ND1000) was used following manufacturer’s protocol, to determine the 
concentration of the plasmid yielded. 
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Table 1: PCR primers 
Gene of 
Interest 
Nucleotide sequence Size of 
Amplicon 
Full length G9a 
Forward 
5’CGGAATTCTATGGGGGCGCTCCTGCTGGAGAA
G 3’ 
 
   3,570 bp 
Full length G9a 
Reverse  
5’CGCTCGAGCCGTTCTCATGTGTTGACAGGGGG 
3’              
G9a-N-terminal 
Forward 
5’CGGAATTCTATGGGGGCGCTCCTGCTGGAGAA
G 3’ 
 
   1,824 bp 
G9a-N-terminal 
Reverse  
5’CGCTCGAGTCACGGAGCTTCTTCCGCCTCTCTG
AC 3’ 
G9a-ANK 
Forward 
5’CGGAATTCTATGTTTCCACCCTCGGCAGTTGTA
CCT 3’ 
 
    693 bp 
G9a-ANK 
Reverse  
5’ CGCTCGAGTCACAGCTCAGGGTTGGCCCC 3’ 
G9a-SET 
Forward 
5’ GCACCATGGGCAGCCATCATC 3’  
   690 bp 
G9a-SET 
Reverse  
5’ GTGAATTCTCAAAACCCTAGCTCCTCCC 3’ 
pCMB-Tag2B 
Forward  
(T3 primer)  
5’ GCTCGAAATTAACCCTCACTAAAG 3’  
1,425 bp 
pCMB-Tag2B 
Reverse  
(T7 primer) 
5’ GGTACCTAATACGACTCACTATAGGG 3’ 
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Table 2: Reagents for PCR insert amplification 
Reagent Amount per reaction  
10X Hifi buffer1 5 µl 
10 mM dNTPs2 1 µl 
50 mM MgSO4
1 2 µl 
Forward Primer (100 mg/ml) 1 µl 
Reverse Primer (100 mg/ml) 1 µl 
Platinum Taq DNA polymerase High 
Fidelity (5U/µl)1 
0.2 µl 
Plasmid DNA (1 ng/µl)3 1 µl 
dH20 38.8 µl 
Total volume 50 µl 
 
1. Platinum Taq DNA Polymerase High Fidelity Kit (Invitrogen 11304011).  
2. 10 mM dNTPs diluted from the 100 mM dNTP set consisting of four 
deoxynucleotides (dATP, dCTP, dGTP, dTTP) (Invitrogen 10297018).  
3. Plasmid DNA: EHMT2/pET28a-LIC plasmid (Addgene 25503) for amplification of 
G9a-SET cDNA; G9a/pCMV-sport6 plasmid (PlasmID HsCD00327594) for the 
amplification of the full length G9a, G9a-N-terminal and G9a-ANK cDNAs; 
CDYL/pCR-BluntII-TOPO plasmid (PlasmID HsCD00347437). 
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Table 3: PCR setting for PCR cloning of the insert 
Temperature Duration  Cycles 
94 °C 2 min 1 cycle 
94 °C 30 sec 35 cycles 
55 °C 30 sec 
68 °C 42 sec2, 1:50 min3, 3:34 min4 
30 °C 1 sec 1 cycle 
 
1. Effendof Mastercycler gradient thermal cycler was used for PCR.  
2. PCR setting for amplification of the G9a-SET and G9a-ANK cDNAs. 
3. PCR setting for amplification of the G9a-N-terminal cDNAs. 
4. PCR setting for amplification of the full length G9a cDNA. 
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Table 4: Reagents for PCR verification of the insert 
Reagent Amount per reaction  
10X PCR buffer1 2.5 µl 
10 mM dNTPs2 1 µl 
50 mM MgCl2
1 1.5 µl 
Forward Primer (100 mg/ml) 1 µl 
Reverse Primer (100 mg/ml) 1 µl 
Taq DNA polymerase (5 U/µl)1 0.2 µl 
Plasmid DNA 1 Colony 
dH20 17.8 µl 
Total volume 25 µl 
 
1. Taq DNA Polymerase Kit (Invitrogen 18038042).  
2. 10 mM dNTPs diluted in dH20 from the 100 mM dNTP set consisting of four 
deoxynucleotides (dATP, dCTP, dGTP, dTTP) (Invitrogen 10297018). 
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Table 5: PCR setting for verification of the insert 
Temperature Time Cycle 
94 °C 5 min 1 cycle 
58 °C  1 min  
30 cycles 
 
72 °C 1 min 
94 °C 1 min 
55 °C 1 min  
1 cycle 72 °C  7 min 
30 °C 1 min 
 
1. Effendof Mastercycler gradient thermal cycler was used for PCR.  
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Restriction digests of the SET domain and pCS3+MT vector 
Restriction digest of the Topo vector containing the SET domain and pCS3+MT 
empty vector were initially performed with Nco1 restriction enzyme, followed by 
phenol/chloroform extraction and restriction digest with EcoRI restriction enzyme. 
Briefly, 2 µg of SET/Topo vector or pCS3+MT, 0.5 µl of the Nco1 (10U/µl, Invitrogen 
15421019) restriction enzyme, 5 µl of 10X Buffer K (Invitrogen 15421019), 5 µl of 
0.01% BSA (Invitrogen 15421019) were mixed using dH20 to make a total reaction 
volume of 50 µl and incubated at 37 °C for 1 hr.  
Phenol/chloroform extraction and ethanol precipitation was performed prior to 
restriction digest with EcoRI restriction enzyme. Briefly, the 50 µl of the SET/Topo 
vector and pCS3+MT vector from the previous restriction digest with Nco1 was mixed 
with 1 volume (50 µl) of Tris-saturated phenol and 1 volume (50 µl) of chloroform. The 
samples were centrifuged at 9,300 x g for 5 min at room temperature.  The upper aqueous 
phase of each sample was transferred to a fresh sterile 1.7 ml tube. An equal volume (50 
µl) of chloroform was added to the samples and mixed. The samples were centrifuged at 
9,300 x g for 5 min at room temperature and the upper aqueous phase of each sample was 
transferred to a fresh sterile 1.7 ml tube. The digested SET domain and pCS3+MT 
plasmids were then precipitated. Briefly, 1/10 the volume (5 µl) of 3 M sodium acetate 
(pH 5.2) along with twice the volume (10 µl) of 95 % ethanol was added to the samples 
and incubated at -20 °C for 1 hr. The samples were then centrifuged at 9,300 x g and the 
supernatant was discarded. The pellet in each sample was washed with 70 % ethanol, 
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vortexed and centrifuged at 4 °C for 20 min. The ethanol was discarded, and the pellet 
was resuspended in 3 µl TE buffer.  
The samples containing either the SET domain/Topo vector or pCS3+MT vector 
digested with Nco1 restriction enzyme were then used in a second restriction digest using 
the EcoRI restriction enzyme. SET domain/Topo vector or pCS3+MT [2 µg (3 µl)] was 
mixed with 0.5 µl of EcoRI restriction enzyme (10U/µl, Invitrogen 15202013), 1 µl of 
10X reaction buffer H (Invitrogen 15202013) and dH20 to make a final reaction volume 
of 10 µl. They were then incubated at 37 °C for 1 hr.  
Gel purification of the restriction digest products and Rapid ligation 
After restriction digest with Nco1 and EcoRI restriction enzymes, the SET domain 
insert and the pCS3+MT vector were run on a 1.2 % agarose gel with SYBR Safe DNA 
Gel Stain (1 in 10,000 dilution) (10,000X, Invitrogen S33102) via gel electrophoresis for 
30 min at 100 V. Gel purification of the insert and vector was performed using the Qiagen 
QIAquick Gel Extraction Kit (28704), following the manufacture’s protocol. After gel 
purification, 1 µl of the insert and the vector were then run on 1 % agarose to verify the 
gel purified products and estimate their concentration. Rapid ligation of the SET domain 
insert and pCS3+MT vector was then performed using T4 DNA Ligase Kit (Invitrogen 
15224-041), following manufacturer’s protocol. A molar ratio of 3:1 insert:vector was 
used as input. Briefly, the insert and vector were mixed with 1 µl T4 DNA ligase (1U/µl, 
Invitrogen 15224017), 4 µl of 5X ligase reaction buffer, 1 µl of 10 mM rATP (Promega 
P1132) with dH20 making a final reaction volume of 20 µl. The reaction was incubated 
for 5 min. Subsequently, 2 µl of the ligation reaction was used in transformation of XL1 
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Blue cells. Briefly, 2 µl of the ligation reaction was gently mixed with 25 µl of XL1 Blue 
cells and incubated on ice for 20 min. The cells were then heat shocked for 45 sec at 42 
C.  The cells were then incubated on ice for 2 min, after which 250 µl of LB was added 
to each transformation. The cells were then grown for 1 hr on a shaker at 37 C. The 
transformed cells (100 µl) were then plated on Amp resistant agar plates and grown 
overnight at 37 C. Colonies were selected (18 colonies) and PCR was performed using 
“G9a-SET Forward” and “G9a-SET Reverse” primers to determine the presence of G9a-
SET/pCS3+MT vector using the reagents and settings listed in Tables 4 and 5, 
respectively. A colony expressing the G9a-SET/pCS3+MT plasmid was inoculated in 200 
ml of LB with Amp (50g/ml) overnight at 37 °C on a shaker. The following day, 
maxiprep was performed using Qiagen’s Endotoxin-free Maxi Plasmid kit (Qiagen 
12362).  
E. myc-G9a, myc-G9a-N-terminal, myc-G9a-Ank 
Full length G9a, myc-G9a-N-terminal, and myc-G9a-ANK constructs were cloned 
from G9a/pCMV-sport6 plasmid (PlasmID HsCD00327594, GenBank: BC020970.1), via 
PCR, into the pCS3+MT vector between EcoRI and Xho1 restriction sites. Initially, the 
G9a/pCMV-sport6 plasmid was prepared using the Qiagen’s Endotoxin-free Maxi 
Plasmid kit (Qiagen 12362), following the manufacturer’s protocol. The inserts (full 
length G9a, G9a-N-terminal and G9a-ANK) were amplified by PRC using Platinum Taq 
DNA polymerase High Fidelity, as previously described, using reagents and PCR setting 
shown in Tables 2 and 3, respectively. The primers used are listed in Table 1. The PCR 
products were run on 1.2 % agarose gel SYBR Safe DNA Gel Stain (1 in 10,000 dilution) 
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(10,000X, Invitrogen S33102) to verify the amplifications. Subsequently, the PCR 
products were purified using Qiagen QIAquick PCR Purification Kit (Qiagen 28106), 
following the manufacturer’s protocol. The purified PCR products were run on a 1.2 % 
agarose gel with SYBR Safe DNA Gel Stain (1 in 10,000 dilution) (10,000X, Invitrogen 
S33102) to estimate the concentration of the PCR products.  
Restriction digests and gel purification of the digested products 
The purified PCR products (full length G9a, G9a-N-terminal and G9a-ANK 
cDNAs) were digested with EcoRI and XhoI restriction enzymes. Briefly, for each insert 
(full length G9a, G9a-N-terminal and G9a-ANK), 2 µg of the PRC product and 2 µg 
pCS3+MT vector were mixed separately in 1.7 ml sterile tubes with 0.5 µl of EcoRI 
restriction enzyme (10 U/µl, Invitrogen 15202013), 0.5 µl of XhoI restriction enzyme 
(10U/µl, Invitrogen 15231012), 2.5 µl of 10X reaction buffer H (Invitrogen 15202013) 
and dH20 making a total reaction volume of 25 µl. The samples were incubated at 37 °C 
for 1 hr. The digested PCR products and pCS3+MT vector were run on a 1.2 % agarose 
gel with SYBR Safe DNA Gel Stain (1 in 10,000 dilution) (10,000X, Invitrogen S33102) 
and gel purified using the Qiagen QIAquick Gel Extraction Kit (28704).  
Rapid ligation and transformation of XL1 Blue cells 
The purified products were run on a 1.2 % agarose gel with SYBR Safe DNA Gel 
Stain (1 in 10,000 dilution) (10,000X, Invitrogen S33102) to estimate their concentration. 
Rapid ligation of the inserts (full length G9a, N-terminal G9a, ANK region) and 
pCS3+MT vector was then performed using T4 DNA ligase kit (Invitrogen 15224-041), 
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following the manufacturer’s protocol. A molar ratio of 3:1 insert:vector was used. 
Briefly, the insert and vector were mixed with 4 µl of 5X ligase reaction buffer, 1 µl T4 
DNA ligase (1U/µl), 1 µl of 10 mM rATP (Promega P1132) with dH20 making a final 
reaction volume of 20 µl. The reaction was incubated for 5 min. Subsequently, 2 µl of the 
ligation reaction was used in transformation of XL1 Blue cells. Briefly, 2 µl of the 
ligation reaction was gently mixed with 25 µl of XL1 Blue cells and incubated on ice for 
20 min. The cells were then heat shocked for 45 sec at 42 C.  The cells were then 
incubated on ice for 2 min, after which 250 µl of LB was added to each transformation. 
The cells were then grown for 1 hr on a shaker at 37 C. The transformed cells (100 µl) 
were then plated on Amp-resistant agar plates and grown overnight at 37 C. Colonies 
were selected (12 colonies for each insert-vector ligation) and PCR was performed using 
primers listed in Table 1 to determine the presence of G9a/pCS3+MT, G9a-N-
terminal/pCS3+MT or G9a-ANK/pCS3+MT plasmid using the reagents and settings 
listed in Tables 4 and 5, respectively. Colonies expressing the desired plasmid were 
inoculated in 200 ml of LB with Amp (50g/ml) overnight at 37 °C on a shaker. The 
following day, maxiprep was performed using Qiagen’s endotoxin-free maxi plasmid kit 
(Qiagen 12362).  
F. pCMV-Tag2B, Flag-CDYL 
pCMV-Tag2B is a flag-tagged empty vector. CDYL was cloned from 
CDYL/pCR-BluntII-TOPO plasmid (PlasmID HsCD00347437, GenBank: BC119682.2) 
into the pCMV-Tag2B vector at the EcoRI restriction site. Initially, the CDYL/pCR-
BluntII-TOPO plasmid was prepared using the Miniprep Kit (Promega A1460), following 
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the manufacturer’s protocol. Nanodrop Spectrometry (Thermo Scientific ND1000) was 
used, following the manufacturer’s protocol, to determine the concentration of the 
plasmid yielded.  
Restriction digests of the CDYL/pCR-BluntII-TOPO plasmid and pCMV-Tag2B empty 
plasmid and gel purification of digested products 
A restriction digest was performed on the CDYL/pCR-BluntII-TOPO and the 
pCMV-Tag2B plasmids performed using EcoRI restriction enzyme. Briefly, 2 µg of 
CDYL/pCR-BluntII-TOPO and pCMV-Tag2B plasmids each, in separate tubes, were 
mixed with 0.5 µl of EcoRI restriction enzyme (10U/µl, Invitrogen 15202013), 5 µl of 
10X reaction buffer H (Invitrogen 15202013) and dH20, making a total reaction volume 
of 50 µl, and incubated at 37 °C for 1 hr. After restriction digest, pCMV-Tag2B vector 
was CIAP treated so the blunt ends do not re-ligate. Briefly, CIAP (Promega M1821) was 
added directly to digested pCMV-Tag2B plasmid; 5 μl CIAP 10X reaction buffer 
(Promega M1821), 0.01 U CIAP/pmol of ends and dH20 to a final volume of 50 μl. It was 
then incubated at 37 °C for 30 min. A second aliquot of diluted CIAP (equivalent to the 
amount used initially) was added and incubated at 37 °C for an additional 30 min. The 
digested CDYL/pCR-BluntII-TOPO and pCMV-Tag2B plasmids were run on a 1.2 % 
agarose gel with SYBR Safe DNA Gel Stain (1 in 10,000 dilution) (10,000X, Invitrogen 
S33102) for 30 min at 100 V and gel purified using the Qiagen QIAquick Gel Extraction 
Kit (Qiagen 28704), following the manufacturer’s protocol.  
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Rapid ligation and transformation of XL1 Blue cells 
The purified products were run on a 1.2 % agarose gel with SYBR Safe DNA Gel 
Stain (1 in 10,000 dilution) (10,000X, Invitrogen S33102) to estimate their 
concentrations. Rapid ligation of the CDYL insert and pCMV-Tag2B vector was 
performed using T4 DNA Ligase Kit (Invitrogen 15224-041), following manufacturer’s 
protocol. A molar ratio of 3:1 insert:vector was used. Briefly, the insert and vector were 
mixed with 5 µl of 5X ligase reaction buffer, 1 µl T4 DNA ligase (1U/µl), 1 µl of 10 mM 
rATP (Promega P1132), with dH20 to make a final reaction volume of 25 µl. The reaction 
was incubated for 5 min. Subsequently, 2 µl of the ligation was used in transformation of 
XL1 Blue cells. Briefly, 2 µl of the ligation was gently mixed with 25 µl of XL1 Blue 
cells and incubated on ice for 20 min. The cells were then heat shocked for 45 sec at 42 
C.  The cells were then incubated on ice for 2 min, after which 250 µl of LB was added 
to each transformation. The cells were then grown for 1 hr on a shaker at 37 C. The 
transformed cells (100 µl) were then plated on Amp-resistant agar plates and grown 
overnight at 37 C. Colonies were selected (18 colonies) and PCR was performed using 
primers listed in Table 1 (pCVM-Tag2B vector primers) to determine the presence of 
CDYL/pCVM-Tag2B plasmid using the reagents and settings listed in Tables 4 and 5, 
respectively. Colonies expressing the CDYL/pCVM-Tag2B plasmid was inoculated in 
200 ml of LB with Amp (50g/ml) overnight at 37 °C on a shaker. The following day, the 
CDYL/pCVM-Tag2B plasmid was prepared using using Qiagen’s endotoxin-free maxi 
plasmid kit (Qiagen 12362).  
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2.11   Plasmid preparation 
Qiagen’s Endotoxin-free Maxi Plasmid kit (Qiagen 12362) was used to prepare all 
plasmids. The sequences/mutations were confirmed by automated dideoxynucleotide 
sequencing of both forward and reverse nucleotide strands, by the Centre for Applied 
Genomics, the Hospital for Sick Children, Toronto, Canada. 
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Table 6: Plasmids 
Plasmid Name Description 
GST-MIER1 GST-tagged full length MIER1. MIER1 cloned into pGEX-
4T-1 vector. 
GST-aa1-283  GST-tagged MIER1 construct protein containing amino acids 
1-283 (cloned into pGEX-4T-1 vector). It contains the ELM2 
domain, but lacks the SANT domain. 
GST-aa287-512  GST-tagged MIER1 construct containing amino acids 287-
512 (cloned into pGEX-4T-1 vector). It contains only the 
SANT domain.   
GST-aa287-357 GST-tagged MIER1 construct containing amino acids 281-
357 (cloned into pGEX-4T-1 vector). It contains the SANT 
domain and the  specific C terminus. 
GST-SANTmutant GST-tagged full length MIER1 with three point mutations at  
326FYY⇾AAA 
pCS3+MT Myc-tagged empty vector. 
Myc-MIER1 Myc-tagged full length MIER1. MIER1 cloned into 
pCS3+MT vector. 
myc-G9a 
 
Myc-tagged full length G9a protein (cloned into pCS3+MT 
vector). 
myc-G9a-N-terminal Myc-tagged G9a construct containing amino acids 21-628 
(cloned into pCS3+MT vector). 
myc-G9a-Ank Myc-tagged G9a construct containing amino acids 649-879 
(cloned into pCS3+MT vector). It contains only the ankyrin 
repeats of G9a protein.  
myc-G9a-SET Myc-tagged G9a construct containing amino acids 913-1142 
(cloned into pCS3+MT vector). It contains only the SET 
domain of G9a protein. 
pCMV-Tag2B Flag-tagged empty vector. 
Flag-CDYL Flag-tagged full length CDYL protein. It is cloned into flag-
tagged pCMV-Tag2B empty vector. 
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2.2   Cell culture  
HEK-293 cell line was purchased from the American Tissue Culture Collection 
and cultured in DMEM (Gibco 11965-092) supplemented with 10 % serum (7.5 % 
newborn calf serum (Gibco 16010-142), 2.5 % fetal calf serum (Gibco 16000-044), 1 mM 
sodium pyruvate (Gibco 11360-070) and 0.5 % penicillin/streptomycin in a humidified 37 
°C incubator with 5 % CO2.   
2.3   Transfection of HEK-293 cells 
Cells were seeded at a density of 5x105 cells/ well in 6 well plates and grown for 
24 hr in DMEM without antibiotics. Following the 24 hr period, cells were transfected 
using the Mirus TransIt-LT1 (Fisher Scientific, MIR 2300) reagent according to 
manufacturer’s protocol. Briefly, 250 μl of serum-free, antibiotic-free Opti-MEM (Gibco 
51985-034) was placed in a sterile tube per transfection. Mirus TransIT-LT1 reagent was 
warmed to room temperature and then added to the 250 μl media, using a 3:1 μl Mirus 
TransIT-LT1 reagent to μg DNA ratio. The solution was gently mixed and plasmid DNA 
was added to the diluted Mirus TransIT-LT1 reagent. The solution was gently mixed 
again and incubated at room temperature for 15 min, following which the Mirus TransIT-
LT1 Reagent – DNA complex was added drop-wise to the cells. The dish was gently 
rocked back and forth and from side to side for even distribution of the Mirus TransIT-
LT1 Reagent – DNA complexes. The cells were then incubated at 37 °C and 5% CO2 for 
48 hr, upon which they were subject to protein extraction and used for 
immunoprecipitation.  
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2.4   GST pull-down assay 
2.4.1   GST-fusion protein production 
 Purified GST protein was kindly provided by Jarratt Rose. GST-tagged MIER1 
constructs either lacking or containing the SANT domain (aa1-283, aa287-512, aa287-
357) and full length MIER1 were prepared by Corinne Mercer, and GST- SANT mutant 
(326FYY⇾AAA) was made by Julia Ferguson. The GST-SANT mutant is full length 
GST-MIER1 protein with 3 point mutations at amino acids 326-328, where the 
phenylalanine and the following two tyrosine residues are mutated to alanine 
(326FYY⇾AAA).  
 Briefly, GST and GST-tagged MIER1 constructs were prepared as follows. The 
pGEX vectors expressing these proteins were transformed into Rosetta ™ 
2(DE3)pLysS Competent Cells (EMD Millipore 71403-3). The plasmid DNA (10 ng) was 
gently mixed with 25 µl of Rosetta cells and incubated on ice for 20 min, following which 
the cells were heat shocked for 45 sec at 42 C. The cells were then incubated on ice for 2 
min, after which 250 µl of LB was added to each transformation. The Rosetta cells were 
then grown for 1 hr on a shaker at 37 C. The transformed cells (100 µl) were then plated 
on Amp-resistant agar plates and grown overnight at 37 C. From the transformed cells, a 
5 ml culture of LB with Amp (50 g/ml) was inoculated and grown overnight on a shaker 
at 37 C. The following day, 250 ml of LB with Amp (50 g/ml) was inoculated with 1 
ml of the overnight culture. It was grown at 37 C on a shaker to an optical density 
(OD600) of 0.8-1.0, at which the culture was induced to make the GST or GST-fused 
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protein by adding 25 l of 1M Isopropyl -D-1-thiogalactopyranoside (IPTG). The 
culture was grown on a shaker overnight at room temperature. The culture was then 
transferred aseptically to a 250 ml Nalgene bottle and centrifuged at 1500 x g at 4 C for 
10 min. The supernatant was drained and the pellet was frozen and thawed to help burst 
the cells open during sonication. The pellet was resuspended in ice cold 5 ml of 1xPBS 
and transferred to a 50 ml Falcon tube. 50 l of 0.2 M phenylmethylsulfonyl fluoride 
(PMSF) (protease inhibitor) was added and the sample was sonicated on ice; 2 pulses, 15 
sec each with 30 sec pause between pulses, 70 % amplitude (Fisher Scientific Sonic 
Dismembrator Model 500). The sample was then transferred to a 30 ml Corex tube and 
500 l of 10 % TritonX-100/1xPBS was added. The sample was then centrifuged at 9,300 
x g at 4 C for 15 min and the aqueous layer was transferred to clean 1.7 ml tubes in 1 ml 
aliquots and stored at -70 C for future applications.  
Prior to use, the expression of GST fusion proteins was verified. For each protein, 
50 l of a 50 % slurry of Glutathione Sepharose 4B beads was washed twice with GST 
pull-down buffer [20 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 10 % glycerol, 0.2 
% NP-40 (in PBS)] in a 1.7 ml tube; 1 ml of GST pull-down buffer was added to the 
beads, inverted to mix and centrifuged for 30 sec at 500 x g. The supernatant was 
aspirated off. The beads were made into a 50 % slurry using GST pull-down buffer. 
Subsequently, 50 µl of the beads were then added to GST pull-down buffer containing the 
soluble protein being tested, along with 5 l of 0.2 M PMSF in a final 1 ml volume. Three 
different volumes of the GST-fused proteins were tested; 50 µl, 100 µl and 200 µl. GST 
pull-down buffer was added to make a total volume of 1 ml for each sample. The samples 
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containing the beads were then rotated at 4 C for 1 hr, after which they were washed 
twice with 1 ml of GST pull-down buffer, and once with 1ml of 150 mM NaCl. The 
supernatant was aspirated and 30 l of 1.5 x SSB [SDS sample buffer (0.125 M Tris-HCl 
pH 6.8, 2 % SDS, 5 % -mercaptoethanol, 20 % glycerol)] + bromophenol blue (dye) was 
added to the beads. The samples were then boiled for 4 min and placed on ice for 2 min. 
The samples were centrifuged at 500 x g for 30 sec and the aqueous layer was loaded on a 
7.5 % SDS-polyacrylamide gel (BioRad 456-1024). Bovine serum albumin (BSA RIA 
grade 1) (Sigma A7888) was also loaded on the gel for determining the approximate 
amount of GST proteins via comparison to known BSA levels. After the gel was run, it 
was removed from the glass plate and placed in Coomassie Blue Stain (0.025 
% Coomassie brilliant blue (BioRad 161-0400), 45 % straight methanol, 10 % glacial 
acetic acid) for 60 min. It was then de-stained overnight with de-stain buffer (30 % 
straight methanol, 10% glacial acetic acid) to remove the excess dye. The gel was then 
dried on Whatman paper for approximately 1 hr at 80 ºC under vacuum.  
2.4.2   GST pull-down assay 
 GST pull-down assay was performed using Glutathione Sepharose 4B beads 
(Qiagen) and GST-tagged MIER1 constructs. For each condition, 50 µl of the 50 % 
slurry of Glutathione sepharose beads were washed with 1 ml of GST pull-down assay 
buffer, followed by a 1 min rotation at room temperature, and centrifugation at 500 x g 
for 30 sec. The supernatant was then aspirated off and the procedure repeated twice. 
Subsequently, beads were resuspended in 1 ml of GST pull-down buffer and were 
incubated with the GST-fused MIER1 proteins (154 nM GST, 23 nM aa1-283, 10 nM 
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aa287-512, 59 nM aa287-357, 10 nM SANTmutant and 12 nM full length MIER1; 
diluted in GST pull down buffer) for one hr at 4 °C on a rotator. Following the 1 hr 
incubation period, the beads were washed 3 times as previously described. Beads were 
then resuspended in 1 ml interaction buffer (GST pull-down buffer with 1mg/ml BSA and 
1mM PMSF) along with 10 nM recombinant G9a protein (diluted in GST pull-down 
buffer) (Origene, TP319200), and rotated for another hr at 4 C. Beads were then washed 
3 times with the GST pull-down buffer and twice with 1 ml of 150 mM NaCl. 
Subsequently, the beads were resuspended in 30 µl of 1.5 x SSB + bromophenol blue 
(dye). Following which, the samples were boiled for 3 min, the supernatant was collected 
and loaded on a 7.5 % SDS-polyacrylamide gel (BioRad 456-1024) and western blot 
analysis was performed. Trans-blot Turbo System was used to transfer the gels onto 
PVDF membranes (BioRad-Trans-blot Turbo Transfer pack 0170-4156) at voltage limit 
of 25 V and constant current of 2.5 A for 10 min.  G9a antibody (1 in 1000 dilution of 1 
µg/µl stock, Millipore 07-441) was used to probe for G9a and GST antibody (1 in 5000 
dilution of 0.5 µg/µl stock, Genscript A00865) was used to detect the level of GST-fused 
proteins used. Table 7 lists all the primary antibodies used. Densitometric analysis was 
carried out using ImageJ software. Densitometric measurements of the amount of G9a 
bound were divided by the densitometric measurements of the amount of GST/GST-
MIER1 constructs to obtain relative amount of G9a interaction with each input.  
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2.5   Immunoprecipitation 
2.5.1   Cell lysate preparation 
For in vivo immunoprecipitation (IP) assay between myc-G9a constructs and 
MIER1, HEK-293 cells were seeded at a density of 5 x 105 cells/well in a 6-well plate 
and grown in DMEM for approximately 24 hr. Subsequently, cells were transfected using 
Mirus TransIT-LT1 Reagent as described on page 54, with 0.5 µg of MIER1 and myc-
FL-G9a or myc-G9a-N-terminal or myc-G9a-ANK or myc-G9a-SET-expressing 
plasmids; 0.5 µg MIER1-expressing plasmid and pCS3+MT empty vector; 0.5 µg myc-
FL-G9a-expressing plasmid and pcDNA3.1 empty vector. For in vivo 
immunoprecipitation (IP) assay between MIER1, flag-tagged CDYL, and myc-tagged 
G9a, cells were transfected with 0.5 µg of MIER1, myc-G9a and flag-CDYL plasmids; 
0.5 µg of MIER1, myc-G9a plasmids and pCMV-tag2b vector; 0.5 µg of MIER1 
plasmid, pCS3+MT vector and flag-CDYL plasmid; 0.5 µg pcDNA3.1 vector, myc-G9A 
and flag-CDYL plasmids; MIER1 plasmid, pCS3+MT empty vector and pCMV+tag2b 
empty vector.  After 48 hr, cells were lysed as follows. Each well was washed with 2ml of 
1x PBS at room temperature, and 500  μl of 1x Triton lysis buffer diluted from a 10x 
stock (0.1 M Tris pH 7.5, 0.1 M EDTA, 0.2 % sodium-azide, 10 % Triton X-100 in 
dH2O) containing 100x PI and 1 mM PMSF; two wells were then combined for each 
condition. A third well was extracted with 500 μl of 1.5 x SSB. After 1xTriton or SSB 
were added, the cells were scraped with cell lifters (Fisher Scientific 08100240) and 
incubated for 20 min on ice. Cell lysates were then pulled through a 1 ml syringe 30 times 
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to shear the DNA, following which they were transferred to labeled, chilled 1.7 ml tubes. 
The cell lysates were then centrifuged at 12,000 x g for 10 min at 4C and the supernatant 
was transferred to another 1.7 ml tube containing protein A agarose beads (Pierce 20333), 
prepared as described below.  
2.5.2   Co-immunoprecipitation  
Protein A agarose beads (Pierce 20333) were washed with 1x Triton medium, 
following a 1 min rotation at room temperature, and centrifugation at 500 x g for 30 
seconds. This was repeated twice, and the final pellet was made into a 50 % slurry of the 
final pellet with 1x Triton buffer. For each IP condition, 50 μl of the 50 % slurry was 
used. For IP between the G9a constructs and MIER1 and for IP between MIER1, flag-
tagged CDYL and myc-tagged G9a, MIER1 antibody was used to pre-bind to the beads 
(1 in 100 dilution). MIER1 antibody was added to the beads along with 990 μl 1 x 
Triton medium and 10 µl PI, and incubated on a rotator for 1 hr at 4 C; preimmune 
serum was used as a negative control. For the reverse IP between myc-G9a constructs and 
MIER1, 9E10 antibody was pre-bound to the beads (1 in 100 dilution). The beads were 
then centrifuged for 30 sec at 0.5 x g and washed twice as described above. After the cell 
lysates were prepared as previously described, they were loaded onto the beads and 
incubated overnight at 4 C.  The samples were washed twice with 1 x Triton medium, 
and once with 150 mM NaCl. The beads were centrifuged for 1 min at 500 x g and 
resuspended in 30 µl 1.5 x SSB + bromophenol blue dye and boiled for 4 min. The beads 
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were then centrifuged again (as described above) and the supernatant was loaded on a 10 
% SDS-PAGE gel (BioRad 456-1034). 
2.5.3   Western blot analysis 
 SDS-PAGE gels (10%) (BioRad 456-1034) were run at 15 mA for approximately 
1.5 hr and were then transferred onto PVDF membranes (BioRad-Trans-blot Turbo 
Transfer pack 171-4146) via Trans-blot Turbo system (BioRad) at voltage limit of 25 V 
and constant current of 2.5 A for 10 min. The membrane was then blocked in 5 % skim 
milk dissolved in lx Tris-Buffered Saline-Tween 20 (TBST) (20 mM Tris pH 7.6. 150 
mM NaCI, 0.1 % Tween-20, and dH20) at room temperature for 1 hr. For myc-G9a 
constructs and MIER1 IPs, 9E10 antibody (1 in 1000 dilution in 5 % skim 
milk/1xTBST) was used to probe for myc-tagged G9a and the various myc-tagged G9a 
constructs, and pan-MIER1 antibody (1 in 1000 dilution) was used to probe for MIER1. 
For IP between MIER1, myc-tagged G9a, and flag-tagged CDYL, 9E10 antibody was 
used to detect myc-tagged G9a and flag antibody (1 in 2000 dilution, Sigma F3165) was 
used to probe for flag-tagged CDYL. For western blot detection of EZH2, EHZ2 antibody 
(1 in 1000, Cell Signaling 5246S) was used. -actin antibody (1 in 5000 dilution, Sigma 
A5441) was used to probe for -actin. Table 7 on page 70 lists the antibodies used for 
western blot analysis (the specificities of the antibodies were confirmed prior to use). All 
antibodies were in 5 % skim milk/1x TBST. The western blots were then incubated on a 
shaker for 3 hr at room temperature, with the exception of -actin antibody which was 
incubated for 1 hr at room temperature. Subsequently, the membranes were washed 
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several times for 1 hr with a total of 1 liter 1 x TBST. The western blots were then probed 
with 1 in 5000 dilution of goat anti-mouse conjugated to horseradish peroxidase 
secondary antibody (0.8 mg/ml stock, Jackson ImmunoResearch 115035174) to detect 
anti-mouse antibodies, or 1 in 2500 dilution of donkey anti-rabbit conjugated to 
horseradish peroxidase secondary antibody (GE Healthcare Life Sciences NA934V) to 
detect EZH2. Table 8 lists the secondary antibodies used. Both secondary antibodies were 
diluted in 5 % skim milk /1x TBS-T, in which the membranes were incubated for 1 hr. 
Subsequently, the membranes were washed several times with 1xTBST for 1 hr at room 
temperature with a total volume of 1 L. The blots were then analyzed using the Clarity 
Blotting system (BioRad 170-5061)/ ECL prime western blotting system (GE Healthcare 
RPN2232) and visualized on ECL hyperfilm (Amersham 45001508). Densitometric 
analysis on CDYL expression was carried out using ImageJ software. 
2.6   Methylation assay using recombinant G9a protein  
2.6.1   Methylation assay using H3(21-44) peptide as the substrate 
 Recombinant purified full length G9a (Origene TP319200), and SET domain 
(Active Motif 31425) were used in this assay. Recombinant SET domain protein contains 
only the SET domain of the G9a protein with its adjacent cysteine rich regions. It includes 
amino acids 913-1193 of the G9a protein, which is responsible for the methylation 
activity. Methylation assay buffer made of 50 mM Tris-HCl pH 9, 1 mM DTT, 0.01 % 
BSA and 1 mM PMSF was used to dilute the proteins and inhibitors used in the assay. 
Recombinant full length G9a, or G9a-SET domain were added to microfuge tubes at 2.5 
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nM and 25 nM, and 2.5 nM and 12.5 nM concentrations, respectively, with and without 
the inhibitors. The samples were incubated without inhibitors or with 200 µM S-adenosyl 
homocysteine (SAH) (Sigma A9384) or with 17µM BIX-01294 (Sigma B9311) for 10 
min at 37 C.  SAH is a common methyltransferase inhibitor (acts via product inhibition), 
and BIX-01294 is a G9a-specific inhibitor. After the 10 min incubation period, the 
samples were incubated with 20 µM S-adenosyl-methionine (SAM) (Sigma A4377) for 
another 10 min. Subsequently, 17 µM H3(21-44) biotinylated peptide (Anaspec 64440) 
diluted in the methylation assay buffer was added to each sample and incubated for 40 
min at 37 C. Each sample had a total reaction volume of 100 µl. SAM was added to the 
reaction prior to the peptide substrate since a study done by Patnaik et al. (2004) showed 
that this causes G9a to have higher methylation activity [39]. 
Streptavidin coated, high-capacity plates (Pierce Thermo Scientific 15501) were 
used in this assay to capture the biotinylated peptide as avidin and biotin have high 
binding affinity towards each other. After the 1 hr total reaction time, streptavidin 8-well 
strips were washed twice with 1x TBST (20 mM Tris pH 7.6. 150 mM NaCI, 0.1 % 
Tween-20, and dH20). The samples were then loaded onto the wells, and incubated for 1 
hr at 4 C, allowing the biotinylated H3(21-44) peptide to bind to the avidin immobilized 
on the wells. Following the incubation, the wells were washed three times with 1xTBST 
and blocked with 150 µl of superblock T20 (TBS) blocking buffer (Thermo Scientific 
37536) for 30 min. After the blocking period, polyclonal histone H3K27me1 (1 µg/µl 
stock, Active Motif 39889) and H3K27me2 (1 µg/µl stock, Active Motif 39919) 
antibodies in 1xPBS (1 in 200 dilution) were added to the wells. The primary antibody 
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was incubated for 1 hr at room temperature, following which the wells were washed three 
times with 1xTBST. Anti-rabbit conjugated to horseradish peroxidase secondary antibody 
in 1x PBS (1 in 2000) was then added to the wells with a 1 hr incubation period. 
Subsequently, the wells were washed once again 3 times with 1x TBST, and 150 µl of 1-
Step ABTS Solution (Thermo Scientific 37615) was added to each well, and incubated 
for 30 min. The reaction was quenched with 100 µl of stop solution (1 % SDS with 0.02 
% sodium azide in dH20). The 8-well strips were then read on a plate reader (BioRad 
Microplate Reader 3550) at λ = 415 nm. Each condition in each experiment was 
performed in duplicate.  The data were normalized and visualised as histogram.  
2.6.2   Methylation assay using recombinant histone 3 as the substrate 
To further elucidate the role of G9a in H3K27 methylation, the activity of 
recombinant SET domain (Active Motif 31425) was tested on whole, recombinant histone 
3.1 (New England Biolabs M2503S), and methylation was detected via western blot 
analysis. This assay was performed with 44 ng SET domain, 0.75 µg recombinant histone 
3.1, 5 µM SAM, and 150 µM SAH, in methylation assay buffer (50 mM Tris-HCl pH 9, 
1mM DTT, 0.01 % BSA, 1 mM PMSF) with a total reaction volume of 30 µl. Initially, 
the SET domain was diluted in the assay buffer and incubated with 150 µM SAH or equal 
amount of buffer for 10 min at 37 C. Subsequently, 5 µM SAM was added to each 
sample, and incubated for 10 min at 37 C. The substrate, 0.75 µg recombinant histone 
H3.1, was then added to each sample and the reaction was incubated for additional 1 hr 
40 min at 37 C. After the incubation period, 10 µl of 4x SSB (SDS sample buffer [200 
mM Tris HCl, 8 % SDS, 20 % -mercaptoethanol, 40 % glycerol]) + bromophenol blue 
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(dye) was added to each sample. The samples were then boiled and loaded on a 4-20 % 
gradient SDS-polyacrylamide gel (BioRad 456-1094). The gels were then transferred 
onto nitrocellulose membrane (BioRad 162-0212) via Trans-blot Turbo System (BioRad) 
at voltage limit of 25 V and constant current of 1.3 A for 5 min. Western blot analysis 
was performed as described earlier. H3K27me2 antibody (1 in 1000 dilution of 1 µg/µl 
stock, Active Motif 39919) was used to detect H3K27 methylation, and H3K9me2 
antibody (1 in 1000 dilution of 1 µg/µl stock, Millipore 07-441) was used to probe for 
H3K9 methylation. H3K9 methylation was tested as a positive control.  
The efficacy of G9a specific inhibitor (BIX-01294, Sigma B9311), EZH2 specific 
inhibitor (GSK-343, Sigma SML0766) and SAH (Sigma A9384) on recombinant SET 
protein was tested in subsequent experiment as well. This was performed to determine if 
BIX and GSK-343 inhibit G9a at the selected concentrations, which may be used in 
future experiments. Only H3K9 methylation was tested as previous experiment showed 
no detectable H3K27 methylation by G9a. The assay was performed as previously 
described, using methylation assay buffer (50 mM Tris-HCl pH 9, 1 mM DTT, 1 mM 
PMSF), 0. 44 ng G9a-SET protein, 0.75 µg recombinant histone 3.1, 5 µM SAM, 150 µM 
SAH, 170 µM BIX-01924, 40 nM GSK-343 and 4 µM GSK-343. All the reagents used 
were initially diluted in the methylation assay buffer. Following the methylation assay, 
western blot analysis was performed as described above. H3K9me2 antibody (1 in 1000 
dilution of 1 µg/µl stock, Millipore, 07-441) was used to detect methylation.  
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2.7   Methylation assay using GST-MIER1 protein and recombinant H3(21-44) 
peptide as the substrate 
To determine the role of MIER1 on H3K27 methylation, GST-MIER1 was used, 
along with GST protein as a negative control. GST protein was kindly provided by Jarratt 
Rose, and full length GST-MIER1 was prepared by Corinne Mercer as previously 
described (pages 55-57). For this assay, a GST pull-down was initially performed as 
previously described (pages 57-58), with minor alterations. Briefly, for each condition 
154 nM GST or 12 nM GST-MIER1 protein was added to 1 ml of GST pull-down buffer 
containing 50 µl of 50 % slurry of glutathione sepharose beads, and incubated for 1 hr at 
4 °C on a rotator. Following the 1 hr incubation period, the beads were washed 3 times as 
previously described (page 57). The GST and GST-MIER1 protein bound to the beads 
were subsequently used in the methylation assay previously described (pages 62-64). The 
beads bound with GST or GST-MIER1 were incubated with 200 µM SAH, 17 µM BIX-
01294, or with equal volume methylation assay buffer for 10 min at 37 °C on a rotator. 
Subsequently, the samples were incubated with 20 µM SAM for another 10 min. 
Inhibitors, SAH and BIX-01294, and the methyl donor, SAM, were diluted in the 
methylation assay buffer (50 mM Tris-HCl pH 9, 1 mM DTT, 1 mM PMSF). Following 
the 10 min incubation period 17 µM H3(21-44) peptide, also diluted in the methylation 
assay buffer, was added to each sample and incubate for  additional 40 min at 37 °C. Each 
sample had a total reaction volume of 100 µl and a total reaction time of 1 hr. After the 1 
hr period, the beads were centrifuged at 500 x g for 30 seconds. The supernatant 
containing the reaction mixture was collected and added to the streptavidin 8-well strips. 
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The detection of the H3K27 methylation followed the same procedure as with 
methylation assay using recombinant G9a previously described (pages 62-64). The wells 
were read by the plate reader and the results were presented as histograms.  
2.8   Methylation assay using MIER1 complex from HEK293 cells 
 HEK-293 cells used to determine if MIER1 immunoprecipitated from cell 
extracts is able to methylate H3K27. As with the immunoprecipitation assay previously 
described, HEK-293 cells were seeded at a density of 5 x 105 cells/well in a 6-well plate 
and grown in DMEM for approximately 24 hr. Cells were then transfected using Mirus 
TransIT-LT1 Reagent with 0.5 µg of pCS3+MT (empty vector), or myc-MIER1 
expressing plasmids. After 48 hr, cells were lysed as follows. Each well was washed with 
2 ml of 1x PBS at room temperature, and 500 μl of 1 x Triton lysis buffer diluted from a 
10x stock (0.1 M Tris pH 7.5, 0.1 M EDTA, 0.2 % sodium-azide, 10 % Triton X-100 in 
dH2O) containing 100x PI and 1 mM PMSF; two wells were then combined for each 
condition. After 1x Triton was added, the cells were scraped with cell lifters (Fisher 
Scientific) and incubated for 20 min on ice. Cell lysates were then pulled through a 1 ml 
syringe 30 times to shear the DNA, following which they were transferred to labeled, 
chilled 1.7 ml tubes. The cell lysates were then centrifuged at 12,000 x g for 10 min at 4 
C and the supernatant was transferred to another 1.7 ml tube containing protein A 
agarose beads pre-bound with 9E10 antibody (1 in 100 dilution).   
Protein A agarose beads were prepared as follows. Protein A beads (Pierce) were 
washed with 1x Triton medium, following a 1 min rotation at room temperature, and 
centrifugation at 0.5 x g for 30 sec. This was repeated twice, and the final pellet was made 
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into a 50 % slurry of the final pellet with 1x Triton buffer. For each IP condition, 50 μl of 
the 50% slurry was used. MIER1 antibody was used to pre-bind to the beads (1 in 100 
dilution). MIER1 antibody was added to the beads along with 990 μl 1 x Triton medium 
and 10 µl 100x PI, and incubated on rotator for 1 hr at 4 C; preimmune serum was used 
as a negative control. The beads were then centrifuged for 30 sec at 0.5 x g and washed 
twice as described above. After the cell lysates were prepared as described above, they 
were loaded onto the beads and incubated overnight at 4 C.  The following day, the 
samples were washed twice with 1 x Triton medium, and once with 150 mM NaCl. The 
beads were then resuspended in the methylation assay buffer and used in the methylation 
assay as follows.  
The immunoprecipated cell lysates were incubated with 200 µM SAH, 17 µM 
BIX-01294, or with equal volume methylation assay buffer for 10 min at 37 C on a 
rotator. Subsequently, the samples were incubated with 20 µM SAM for another 10 min. 
Inhibitors, SAH and BIX-01294, and the methyl donor, SAM, were diluted in the 
methylation assay buffer (50 mM Tris-HCl pH 9, 1 mM DTT, 1 mM PMSF). Following 
the 10 min incubation period 17 µM H3(21-44) peptide, also diluted in the methylation 
assay buffer, was added to each sample and incubate for  additional 40 min at 37 C. Each 
sample had a total reaction volume of 100 µl and a total reaction time of 1 hr. After the 1 
hr period, the beads were centrifugation at 0.5 x g for 30 sec. The supernatant containing 
the reaction mixture was collected and added to the streptavidin 8-well strips. The 
detection of H3K27 methylation followed the same procedure as with methylation assay 
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using recombinant G9a previously described (pages 62-64). The wells were read by the 
plate reader and the results were presented as histograms. 
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Table 7: Primary antibodies  
Name Description 
9E10 Mouse monoclonal anti-myc antibody  
-actin Mouse monoclonal anti--actin antibody 
purchased from Sigma (A5441). 
EZH2 Rabbit monoclonal anti-EZH2 antibody 
purchased from Cell Signaling (5246S). 
GST Mouse monoclonal anti-GST antibody 
purchased from Genscript (A00865).  
G9a  Rabbit polyclonal anti-G9a antibody 
purchased from Millipore (07-551). 
H3K9me2 antibody Rabbit polyclonal anti-dimethyl-histone H3 
(Lys9) antibody purchased from Millipore 
(07-441).   
H3K27me1 antibody Rabbit polyclonal anti-monomethyl-histone 
H3 (Lys27) antibody purchased from 
Active Motif (39889). 
H3K21me2 antibody Rabbit polyclonal anti-monomethyl-histone 
H3 (Lys27) antibody purchased from 
Active Motif (39919). 
Histone H3.1 antibody Rabbit monoclonal anti-histone H3.1 
antibody purchased from Cell Signalling 
(4499S).  
Flag  Mouse monoclonal anti-Flag M2 antibody 
purchased from Sigma (F3165). 
Immunogen sequence: DYKDDDK. 
pan-MIER1 Mouse monoclonal MIER1 antibody. It 
recognizes both  and  MIER1 isoforms. 
Prepared by immunizing rabbits with 
16CSDDHEFGPSTDMLVHD32  synthetic 
peptide of the predicted MIER1 protein 
sequence [101] 
MIER1 In house rabbit polyclonal MIER1 
specific antibody. Prepared by immunizing 
rabbits with 413CQMLLPVHFSAISSR426  
synthetic peptide of the predicted MIER1 
protein sequence [101]. 
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Table 8: Secondary antibodies 
Name Description 
Donkey anti-rabbit Donkey anti-rabbit conjugated to 
horseradish peroxidase secondary antibody 
purchased from GE Healthcare Life 
Sciences (NA934V). 
Goat anti-mouse  Light chain specific goat anti-mouse 
conjugated to horseradish peroxidase 
secondary antibody purchased from 
Jackson ImmunoResearch (115035174).  
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Chapter 3: Results 
 
3.1 Interaction between MIER1 and G9a 
3.1.1    In vitro interaction between MIER1 and G9a 
 To determine whether MIER1 and G9a interact in vitro, GST pull-down assays 
were performed. Moreover, GST-tagged deletion constructs of MIER1 (Fig. 6A) were 
used in the GST pull-down to further determine, if the two proteins interact, which region 
of MIER1 is involved in this interaction. GST-fusion constructs either lacking or 
containing the SANT domain [GST, aa1-283, aa287-512, aa287-357, 
SANTmutant(326FYY-AAA) and full length MIER1 were used to determine which 
region in MIER1 plays an important role in the recruitment of G9a. Recombinant full 
length G9a (Origene) was used for this assay.  The relative amount of GST-fused proteins 
used in the assay is shown by Western blot analysis (Fig. 6D).  
The GST pull-down assay showed that MIER1 interacts with G9a in vitro as 
evident in Fig. 6B-C. Moreover, the region of MIER1 that is responsible for this 
interaction contains the SANT domain. The construct that lacks the SANT domain, aa1-
283, does not interact with G9a (Fig. 6B), further confirming the role of SANT domain in 
MIER1-G9a interaction. Nonetheless, the SANT mutant (which contains the FYY to 
AAA amino acid change at aa326-328) also interacts with G9a (Fig. 6B), which suggests 
that these conserved amino acids are not responsible for MIER1-G9a interaction. 
Furthermore, there is some interaction seen with GST alone; however, this could be 
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because of the relatively higher amount of GST protein used (Fig. 6D), causing 
nonspecific binding. When the amount of G9a bound is normalised to the amount of 
GST/GST-MIER1 constructs, there is greater amount of G9a binding to GST-MIER1 
than to GST protein (Fig. 6C).     
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Figure 6: GST pull-down showing the interaction between G9a and GST-MIER1 
fusion constructs in vitro 
 
Interaction between GST-fusion proteins [GST, aa1-283, aa287-512, aa287-357, 
SANTmutant(326FYY-AAA) and MIER1]  and purified recombinant G9a (Origene). 
GST-fusion proteins were prepared and GST pull-down assay was performed three times 
as described in Materials and Methods section. The GST pull-down assay was repeated 
three times. A) Schematic representation of the GST-MIER1 constructs used in the 
assay. B) The amount of G9a binding to GST and GST-MIER1 constructs. G9a antibody 
was used to probe for the recombinant G9a protein. C) The relative amount of G9a bound 
as calculated using ImageJ densitometry analysis of the blots (level of G9a bound/amount 
of GST-MIER1 construct). D) The levels of GST-MIER1 constructs used in the assay, 
detected using GST antibody.  
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3.1.2    In vivo interaction between MIER1 and G9a 
To determine whether MIER1 and G9a interact in vivo, HEK-293 cells were 
transiently transfected with 0.5 µg of MIER1 and full length G9a (myc-FL-G9a) or the 
N terminal (myc-G9a-N-terminal; aa 21-628) or the ankyrin repeats (myc-G9a-ANK; aa 
649 – 879) or the SET domain of G9a (myc-G9a-SET; aa 913-1142)-expressing plasmids; 
0.5 µg MIER1-expressing plasmid and pCS3+MT empty vector; 0.5 µg myc-FL-G9a-
expressing plasmid and pcDNA3.1 empty vector. Fig. 7A shows the myc-tagged deletion 
constructs of G9a used in the co-immunoprecipitation assay; full length G9a protein; N-
terminal of G9a protein containing the cysteine rich region; ankyrin repeats; and SET 
domain.  
Initially, cells extracts were immunoprecipitated with MIER1 antibody which 
specifically recognizes the  isoform of MIER1 and probed for G9a with 9E10 antibody. 
Cell extracts were also immunoprecipitated with preimmune serum, as a negative control. 
As evident in Fig. 7B, MIER1 interacts with G9a in its full length form and weakly with 
the N-terminal; it doesn’t interact with the other G9a constructs. The weak interaction 
seen with the N-terminal of G9a protein could be non-specific as its expression is 
relatively high compared to other myc-tagged G9a proteins. 
Subsequently, HEK-293 cells were transiently transfected with 0.5 µg of MIER1 
and myc-FL-G9a or myc-G9a-N-terminal or myc-G9a-ANK or myc-G9a-SET constructs; 
0.5 µg MIER1 expressing plasmid and pCS3+MT empty vector; or 0.5 µg myc-FL-G9a 
plasmid and pcDNA3.1 empty vector. This time, however, a reverse co-
immunoprecipitation was performed, where G9a constructs were immunoprecipitated 
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using 9E10 antibody, and probed for MIER1 using pan-MIER1 antibody. Once again, as 
evident in Fig. 7C, MIER1 only interacts with full length G9a; the deletion constructs 
do not interact with MIER1 in HEK-293 cells in vivo.  
  Expression of MIER1 and myc-tagged G9a constructs for both co-
immunoprecipitations was verified by Western blot analysis of whole cell lysates 
(extracted in 1.5x SSB) using pan-MIER1 antibody, which recognizes both MIER1 and 
MIER1 isoforms, and 9E10 antibody which recognizes the myc-tag G9a constructs. For 
MIER1, it is the bottom band that corresponds to the protein. The predicted molecular 
weight of MIER1 is 49 kDa but it runs slower on SDS-PAGE gels at 63-75 kDa. The 
top band which runs between 75-100 kDa, is possibly endogenous MIER1, which is 
larger than MIER1. MIER13A isoform is also larger than MIER1, which results from 
the inclusion of the cassette exon, exon 3A. The antibody could be detecting endogenous 
levels of MIER13A as the pan-MIER1 antibody used is not isoform specific. MIER1 
and MIER1 specific antibodies could be used to determine definitely what protein the 
top band is. Similarly, the band can be cropped out from the gel and mass spectrometry 
could be performed to determine the protein. Moreover, it can also be a non-specific band 
that is being detected by the primary and secondary antibodies. -actin antibody was used 
to probe for -actin, which is used as a loading control for the cell lysates. The levels of 
-actin are similar in all the lanes indicating that equal amount of cell lysates were loaded 
in each lane.    
 
  
Figure 7: MIER1 interacts with G9a in HEK 293 cells 
HEK-293 cells were seeded at a density of 5 x 105 cells/well in a 6-well plate and 
grown in DMEM for approximately 24 hr, following which cells were transfected with 
0.5 µg of MIER1 and myc-FL-G9a or myc-G9a-N-terminal or myc-G9a-ANK or myc-
G9a-SET constructs; 0.5 µg MIER1 plasmid and pCS3+MT empty vector; or 0.5 µg 
myc-FL-G9a plasmid and pcDNA3.1empty vector. Cell lysates were prepared as 
described in Materials and Methods section, and western blot was performed (lanes 1-7). 
6A) Schematic representation of the myc-tagged deletion constructs of G9a used in the 
assay. 6B) The top panel shows the MIER1-G9a complex immunoprecipitated using 
MIER1 antibody and preimmune serum (negative control), and western blotted for G9a 
using 9E10 antibody. The bottom western blots shows the cell extracts probed for G9a 
using 9E10 antibody and for MIER1 using MIER1 antibody (the bottom band seen in 
the western blot is MIER1). They show the expression levels of the transfected proteins. 
-actin antibody was used to probe for -actin, which is used as a loading control for the 
cell lysates. 6C) The MIER1-G9a complex immunoprecipitated using 9E10 antibody 
(immunoprecipitated myc-tagged G9a), and western blotted for MIER1 using MIER1 
antibody. The bottom western blots shows the expression level of the transfected proteins. 
9E10 antibody was used to detect myc-G9a constructs and pan-MIER1 antibody to detect 
MIER1 (the bottom band seen in the western blot is MIER1). -actin antibody was 
used to probe for -actin, which is used as a loading control for the cell lysates.  
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3.2 Interaction between MIER1, G9a, CDYL and EZH2 
3.2.1   In vivo interaction between MIER1, G9a and CDYL 
 Co-immunoprecipitation assay was performed between MIER1, G9a, and CDYL 
to determine whether these proteins interact and exist as a complex in vivo. HEK-293 
cells were seeded at a density of 5 x 105 cells/well in a 6-well plate and grown in DMEM 
for approximately 24 hr. Cells were then transiently transfected with: 1) 0.5 µg MIER1, 
myc-G9a and flag-CDYL plasmids; 2) 0.5 µg MIER1, myc-G9a and pCMV Tag2b 
empty vector; 3) 0.5 µg MIER1a, pCS3+MT empty vector and flag-CDYL; 4)  0.5 µg 
pcDNA3.1empty vector, myc-G9A and flag-CDYL; 5) 0.5 µg MIER1, pCS3+MT 
empty vector and pCMV+tag2b  empty vector. Cell lysates were immunoprecipitated 
using MIER1 antibody, and a Western blot analysis was performed. The MIER1-G9a-
CDYL complex was also immunoprecipitated with preimmune serum as a negative 
control (Fig. 8A).  Additionally, the expression of the transiently transfected proteins was 
checked by Western blot analysis. For both, immunoprecipitation (Fig. 8A) and cell 
lysate western blots (Fig. 8B), pan-MIER1 antibody was used to detect MIER1, flag 
antibody was used to probe for flag-tagged CDYL, and 9E10 antibody was used to 
visualise myc-tagged G9a.  
As evident by Fig. 8, G9a and CDYL both interact with MIER1. Moreover, 
MIER1 interacts with CDYL independent of G9a being present or not (Fig. 8, lane 4). 
This is the same with MIER1-G9a interaction; MIER1 interacts with G9a independent 
of CDYL (Fig. 8, lane 3). When CDYL is transiently transfected alongside MIER1 and 
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G9a, MIER1-G9a interaction is neither amplified nor diminished (Fig. 8, lane 2), and 
vice versa, suggesting that CDYL is not a bridging protein between MIER1 and G9a. 
Lanes 4 and 5 in Fig. 8 serve as additional negative controls. Lane 4 shows no G9a and 
CDYL binding to MIER1 as there is no MIER1 transfected into the cells; when the 
cell lysates are immunoprecipated with MIER1 antibody and there is no MIER1 
transfected in the cells, there should be no G9a or CDYL co-immunoprecipated. This is 
evident in Fig. 8 lane 4; there is no non-specific G9a or CDYL binding to the beads. Fig. 
8 lane 5 shows no G9a and CDYL binding either since neither protein is transfected; only 
MIER1 is transfected. The absence of bands shows that 9E10 and flag antibody used to 
probe for G9a and CDYL are myc-tagged and flag-tagged specific.  
The expression of MIER1a is greater in lane three compared to other lanes where 
it is transfected. This could be due to error in transfection of the MIER1-expressing 
plasmid. The levels of G9a expressed in each condition are similar as shown by Fig. 7B. 
CDYL expression, however, differs with and without the expression of MIER1. When 
MIER1 is expressed in cells, there is increased CDYL expression.  -actin antibody was 
used to probe for -actin, which is used as a loading control for the cell lysates. The 
levels of -actin are similar in all the lanes indicating that equal amount of cell lysates 
were loaded in each lane.    
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Figure 8: MIER1 interacts with G9a and CDYL in HEK 293 cells.  
HEK-293 cells were seeded at a density of 5 x 105 cells/well in a 6-well plate and 
grown in DMEM for approximately 24 hr. Cells were then transiently transfected with: 1) 
0.5 µg MIER1, myc-G9a and flag-CDYL; 2) 0.5 µg MIER1, myc-G9a and pCMV-
tag2b vector; 3) 0.5 µg MIER1, pCS3+MT vector and flag-CDYL; 4) 0.5 µg pcDNA3.1 
vector, myc-G9A and flag-CDYL; 5) 0.5 µg MIER1, pCS3+MT vector and 
pCMV+tag2b vector. Cell lysates were prepared as described in Materials and Methods 
section, and Western blot was performed (lanes 1-6). The co-immunoprecipitation was 
replicated three times. A) MIER1-G9a-CDYL complex was immunoprecipitated using 
MIER1 antibody and preimmune serum (negative control). B) Cell lysates showing the 
expression level of transiently transfected proteins. Monoclonal pan-MIER1 antibody was 
used to detect MIER1, monoclonal flag antibody was used to probe for CDYL and 
monoclonal 9E10 antibody was used to visualise myc-G9a. -actin antibody was used to 
probe for -actin, which is used as a loading control for the cell lysates.  
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3.2.2   In vivo interaction between G9a and CDYL 
Co-immunoprecipitation assay was performed between G9a and CDYL to 
determine whether these proteins interact in vivo. HEK-293 cells were seeded at a density 
of 5 x 105 cells/well in a 6-well plate and grown in DMEM for approximately 24 hr. 
Subsequently, cells were transiently transfected with: 1) 0.5 µg myc-G9a and 1 µg flag-
CDYL plasmids; 2) 0.5 g pCS3+MT empty vector and 1 g flag-CDYL plasmid; 3) 0.5 
µg myc-G9a plasmid and 1 µg pCMV-Tag2B empty vector. Following 48 hr, cell lysates 
were immunoprecipated using 9E10 antibody which recognises myc-tagged G9a, and 
Western blot analysis was performed. The expression of the transiently transfected 
proteins was checked by Western blot analysis as well. For both, immunoprecipitation 
(Fig. 9A) and cell lysate western blots (Fig. 9B), flag antibody was used to probe for 
CDYL, and 9E10 antibody was used to visualise myc-G9a. As evident by Fig. 9A, G9a 
and CDYL do not interact in vivo. The expression of CDYL is low in comparison to G9a 
(Fig. 9B). However, in previous co-immunoprecipitation assay between MIER1, G9a and 
CDYL (Fig. 8), CDYL strongly interacted with MIER1 with low levels of CDYL protein 
being expressed. 
Densitometry measurements were performed on the Western blot bands 
representing the CDYL expression levels in both figures (Fig. 8 and Fig. 9). CDYL 
expression in Fig. 8 is higher when MIER1 is also expressed; with MIER1 expression, 
densitometry reading of the CDYL band is 16212; without MIER1 expression, it is 
4253. CDYL expression is about 3.8 times greater when MIER1 is also expressed in 
HEK-293 cells. In Fig. 9, when CDYL and G9a are expressed without MIER1, CDYL 
 82 
expression is low with a densitometry reading of 10056, but it is higher than in Fig. 8 
when only G9a and CDYL are expressed (densitometry reading of 4253). Thus, the lack 
of interaction seen between G9a and CDYL is not due to low levels of CDYL, since 
CDYL interacts with MIER1 with similar expression levels.   
 -actin antibody was used to probe for -actin as a loading control for the cell 
lysates. The levels of -actin are similar in all the lanes indicating that equal amount of 
cell lysates were loaded in each lane.    
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Figure 9: G9a and CDYL do not interact in vivo in HEK 293 cells 
 
HEK-293 cells were seeded at a density of 5 x 105 cells/well in a 6-well plate and 
grown in DMEM for approximately 24 hr. Cells were then transiently transfected with: 1) 
0.5 µg myc-G9a and 1µg flag-CDYL plasmids; 2) 0.5 µg pCS3+MT empty vector and 1 
µg flag-CDYL plasmid; 3) 0.5 µg myc-G9a plasmid and 1 µg pCMV-tag2b empty vector. 
Cell lysates were prepared as described in Materials and Methods section, and Western 
blot was performed (lanes 1-3). The co-immunoprecipitation was repeated three times. A) 
G9a-CDYL complex was immunoprecipitated using 9E10 antibody. B) Cell lysates 
showing the expression level of transiently transfect proteins. Monoclonal flag antibody 
was used to probe for CDYL and monoclonal 9E10 antibody was used to visualise myc-
G9a. -actin antibody was used to probe for -actin as a loading control for the cell 
lysates 
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3.2.3   In vivo interaction between MIER1, CDYL and EZH2 
Co-immunoprecipitation assay was performed between MIER1 and CDYL to 
determine whether CDYL acts as a bridging protein between MIER1 and EZH2 in vivo. 
CDYL has been shown to interact with EZH2 [96]. HEK-293 cells were seeded at a 
density of 5 x 105 cells/well in a 6-well plate. After being grown in DMEM for 
approximately 24 hr, the cells were transiently transfected with: 1) 0.5 µg myc-MIER1 
and 1 µg flag-CDYL plasmids; 2) 0.5 g pCS3+MT empty vector and 1 g flag-CDYL 
plasmid; 3) 0.5 µg myc-MIER1 plasmid and 1 µg pCMV-tag2b empty vector. 
Following 48 hr, cell lysates were immunoprecipated using 9E10 antibody which 
recognises myc-MIER1, and Western blot analysis was performed (Fig. 10A). The 
expression of the transiently transfected proteins was checked by Western blot analysis 
(Fig. 10B). Flag antibody was used to probe for CDYL, 9E10 antibody was used to detect 
myc-MIER1, and EZH2 antibody was used for EZH2 visualisation. -actin antibody 
was used to probe for -actin as a loading control for the cell lysates.  
Fig. 10A shows EZH2 interaction with MIER1 only when CDYL is transiently 
transfected alongside MIER1. This suggests that CDYL bridges EZH2, enabling it to 
interact with MIER1. Fig. 9B shows the expression level of EZH2, MIER1 and 
CDYL. With the exception of CDYL, the proteins have relatively similar expression in 
each sample. The expression of CDYL is higher in lane 1 of Fig. 10B, than lane 
2.Potential explanation for this deviation in CDYL expression could have been possible 
inaccuracies in transfection of the CDYL-expressing plasmid. However, this experiment 
was repeated three times, with equal amount of the CDYL-expressing plasmid transfected 
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in each condition, all of which yielded the same result. The expression of CDYL is higher 
when MIER1 is transfected alongside which is also evident in Fig. 8. It is possible that 
MIER1 itself could have an effect on CDYL expression. -actin expression level is 
similar in all the lanes, which signifies that equal amount of cell lysates were loaded in 
each lane. Further experiments are needed to determine if MIER1 is responsible for this 
augment in CDYL expression.   
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Figure 10: CDYL bridges EZH2 to MIER1 in vivo  
 
HEK-293 cells were seeded at a density of 5 x 105 cells/well in a 6-well plate and 
grown in DMEM for approximately 24 hr. Following which, cells were transiently 
transfected with: 1) 0.5 µg myc-MIER1 and 1µg flag-CDYL plasmid; 2) 0.5µg 
pCS3+MT empty vector and 1µg flag-CDYL plasmid; 3) 0.5µg myc-MIER1  plasmid 
and 1 µg pCMV-tag2b empty vector. Cell lysates were prepared as described in Materials 
and Methods section, and Western blot was performed (lanes 1-3). The co-
immunoprecipitation was repeated three times. A) MIER1-CDYL complex was 
immunoprecipitated using 9E10 antibody. B) The expression level of transiently 
transfected proteins (MIER1 and CDYL) and endogenous EZH2.  Flag antibody was 
used to probe for CDYL, 9E10 antibody was used to detect MIER1, and EZH2 antibody 
was used to visualise EZH2. -actin antibody was used to probe for -actin as a loading 
control for the cell lysates.  
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3.3 Histone 3 lysine 27 methylation using recombinant G9a protein 
3.3.1   Methylation assay using H3(21-44) peptide as the substrate 
Recombinant G9a was used to determine whether G9a is able to methylate H3K27 
via the methylation assay using the ELISA approach described in Methods and Materials 
section 2.6.1 (pages 62-64). The activity of G9a from two sources was tested; the SET 
domain from Active Motif, and the full-length G9a protein from Origene. Two 
concentrations of the enzyme were tested, 2.5 nM and 12.5 nM or 2.5 nM and 25 nM for 
the SET domain and for the full-length G9a, respectively, with 20 µM SAM, and two 
different inhibitors; 200 µM SAH and 17µM BIX-01294.  
As evident in Figure 11, only the SET domain has some methytransferase activity 
in this assay, while the full length G9a does not, suggesting that the full length 
recombinant protein is inactive at these concentrations. The SET domain has higher 
activity at the higher concentration (12.5 nM) than at the lower concentration (2.5 nM), 
which indicates specificity. The activity of the SET domain is attenuated in the presence 
of the inhibitors SAH and BIX.  
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Figure 11: Recombinant G9a-SET protein weakly methylates lysine 27 on histone 
H3 peptide  
 
The activity of recombinant G9a containing only the SET domain (Active motif), 
and the full-length protein (Origene) was tested using the Elisa method as described in 
Materials and Methods section. Mono- and di-methylation of the peptide substrate was 
detected using H3K27me1 and H3K27me2 antibodies (Active motif). Two concentration 
of the enzyme were tested, 2.5nM and 12.5 nM or 2.5 nM and 25 nM for the SET domain 
and for the full-length G9a, respectively, with 20 µM SAM, and two different inhibitors; 
200 µM SAH and 17 µM BIX. The methylation assay was performed with a total reaction 
time of 1 hr at 37 C. Equimolar H3(21-44)K27me2 peptide (17 µM) as the unmodified 
H3(21-44) peptide substrate was loaded on the streptavidin coated plates. This illustrates 
the maximum attainable methylation level and is represented by the blue line on the 
secondary y-axis. Two independent experiments were performed, each having a duplicate 
experiment conducted in parallel; average of the experiments is depicted in the bar graph. 
Error bars show the minimum and maximum values as read by the plate reader.  
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3.3.2   Methylation assay using recombinant histone as the substrate 
The purpose of this assay was to determine whether G9a is able to mono- or di-
methylate H3K27 on recombinant histone 3 (H3), with and without the methyltransferase 
inhibitor, SAH, which works via product inhibition. When the methyl group is transferred 
from SAM to the lysine on H3, SAH is produced. Thus, when SAH is initially added, it 
prevents the reaction from going forward and producing more SAH, following Le 
Chatelier’s Principle [117]. H3K9 methylation was also tested as a positive control since 
G9a’s ability to methylate H3K9 has been extensively studied [38]. The methylation 
assay was performed using recombinant G9a-SET protein as described in Methods and 
Materials section, using 44 ng G9a-SET protein, 0.75 µg recombinant histone 3.1, 5 µM 
SAM, and 150 µM SAH.  
Western blot analysis of the samples was performed to detect methylation. The 
unmethylated recombinant histone 3.1 used in the assay was detected using histone 3.1 
antibody, as seen in Fig. 12. H3K27me1and H3K27me2 antibodies were used to detect 
H3K27 methylation, and H3K9me2 antibody was used to check for H3K9 methylation. 
G9a-SET protein methylates H3K9 as seen in Fig. 12. This methylation is attenuated in 
the presence of SAH. G9a-SET protein is not able to methylate H3K27 as there is no 
band detected with H3K27me1 and H3K27me2 antibodies. H3 substrate is present but 
there is no mono- and di-methylated H3K27 detected.  
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Figure 12: Recombinant G9a-SET protein methylates lysine 9 but not 27 on histone 
H3 
 
The activity of recombinant G9a containing only the SET domain (Active motif) 
on H3K9 and H3K27 was tested and detected via western blot analysis, as described in 
Materials and Methods section. This assay was performed using 44 ng SET domain, 0.75 
µg recombinant histone 3.1, 5 µM SAM, and 100 µM SAH, in methylation assay buffer 
(50 mM Tris-HCl pH 9, 1 mM DTT, 0.01 % BSA, 1 mM PMSF) with a total reaction 
volume of 30 µl. The total reaction time was 2 hr at 37 C. Histone H3 antibody was used 
to detect H3 used in the assay. H3K27me1and H3K27me2 antibodies were used to detect 
H3K27 mono- and di-methylation, and H3K9me2 antibody was used to probe for H3K9 
di-methylation. H3K9 methylation was tested as a positive control.  
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3.3.3   Methylation assay using recombinant histone 3 (H3) as the substrate: effects 
of different inhibitors on G9a activity   
Recombinant G9a-SET protein was used to test the potency of different inhibitors. 
H3K9 methylation was solely tested as previous experiment showed no H3K27 
methylation by SET-G9a. The assay was performed as described in Methods and 
Materials section, using 44 ng G9a-SET protein, 0.75 µg recombinant histone 3.1, 5 µM 
SAM, and three difference inhibitors, 150 µM SAH, 170 µM BIX-01924, and 40 nM 
GSK-343.  SAH is a common methyltransferase inhibitor (acts via product inhibition), 
BIX-01294 is a G9a specific inhibitor, while GSK-343 is EZH2 methyltransferase 
specific inhibitor.   
Western blot analysis of the samples was performed and H3K9me2 antibody (1 in 
1000 dilution of 1 µg/µl stock, Millipore, 07-441) was used to detect H3K9 di-
methylation.  A 10 % input of the recombinant histone 3.1 used in the assay was also 
loaded, as seen in Fig. 13, lane 1, which was probed for using histone 3.1 antibody. 
Moreover, G9a di-methylates H3K9 as evident by the presence of band detected by 
H3K9me2 antibody. SAH and BIX-01294 inhibit G9a activity and thus no band is 
detected on the western blot. GSK-343 is not a G9a inhibitor, as it is a specific EZH2 
methyltransferase inhibitor. Thus, in the presence of GSK-343, G9a activity is not 
diminished and H3K9me2 is still detected.  
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Figure 13: The activity of recombinant G9a-SET protein is inhibited by S-adenosyl 
homocysteine (SAH), and the G9a specific inhibitor, BIX-01294, but not GSK-343.  
 
The activity of recombinant G9a-SET protein (Active motif) on H3K9 with and 
without inhibitors was tested and detected via western blot analysis, as described in 
Materials and Methods section. The assay was performed using 44 ng SET domain, 0.75 
µg recombinant histone 3.1, 5 µM SAM, 100 µM general inhibitor SAH, 170 µM G9a 
specific inhibitor BIX-01294, and 40 nM and 4 uM EZH2 specific inhibitor GSK-343, in 
methylation assay buffer (50 mM Tris-HCl pH 9, 1 mM DTT, 0.01 % BSA, 1 mM 
PMSF) with a total reaction volume of 30 µl. Total reaction time was 2 hr at 37 C. 
Histone H3 antibody was used to detect H3 used in the assay (10 % input), and rabbit 
polyclonal H3K9me2 antibody was used to probe for H3K9 methylation.  
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3.4   Histone 3 lysine 27 methylation using GST-MIER1 
 To determine whether MIER1 itself has innate methyltransferase capabilities, 
GST-tagged MIER1 was used to check H3K27 methylation using ELISA. GST and 
GST-MIER1 were prepared and the assay was performed as described in the 
“Methylation Assay using GST-MIER1 Protein” section in Methods and Materials 
chapter. Two independent experiments were carried out, each having a duplicate 
experiment performed in parallel. The results were normalized to sample containing only 
the substrate peptide and graphed as histogram, Fig. 14.  
 Equimolar H3(21-44) K27me2 peptide (17 µM) as H3(21-44) peptide lacking any 
other PTMs was loaded on the streptavidin coated plates, which represents the maximum 
attainable amount of methylation on the histone peptide. In other words, if all the H3(21-
44) peptide used in the assay is methylated by GST-MIER1, it will reach the level 
indicated by the blue line going across the graph in Fig. 14. There is no significant 
difference between GST protein by itself (negative control) and GST-MIER1 protein. 
This indicates that MIER1 does not methylate H3K27. However, there is no positive 
control in this assay to show that the assay itself was functional.  
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Figure 14: GST-MIER1 does not methylate lysine 27 on histone H3 peptide 
 
The activity of GST-fused MIER1 was tested using the ELISA method as 
described in Materials and Methods section, and compared to the GST protein by itself. 
GST and GST-MIER1 were tested under two conditions; with and without inhibitor; 20 
µM SAM, and 200 µM SAH. The methylation assay was performed with a total reaction 
time of 1 hr at 37C. Mono- and di-methylation of the peptide substrate was detected 
using H3K27me1 and H3K27me2 antibodies (Active motif). Equimolar H3(21-44) 
K27me2 peptide (17 µM) as H3(21-44) peptide substrate was loaded on the streptavidin 
coated plates; illustrates the maximum attainable methylation activity (blue line). Two 
independent experiments were performed, each having a duplicate (performed in parallel) 
within experiment; average of the experiments is depicted in the bar graph. Error bars 
show the minimum and maximum values as read by the plate reader. 
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3.5   Histone 3 lysine 27 methylation by endogenous MIER1 complex 
HEK-293 cells were transfected with empty myc (pCS3+MT) vector or myc-
MIER1 plasmid. Initially, cell lysates were collected and the MIER1 complex was 
immunoprecipitated using MIER1 antibody. Subsequently, the immunoprecipitated 
MIER1 complex was used in methylation assay described in Materials and Methods 
section. The assay was normalised with sample containing only the H3(21-44) peptide 
(the amount of methylation activity detected by the plate reader in the sample containing 
just the substrate [H3(21-44) unmodified peptide was subtracted from each sample] and 
the results were graphed as shown in Figure 15. The purpose of this assay was to check if 
the MIER1 complex immunoprecipitated from HEK-293 cells can methylate H3K27. 
The negative control shows the methylation activity of samples containing 
immunoprecipitated lysates from cells transfected with empty myc (pCS3+MT) vector. 
Equimolar H3(21-44) K27me2 peptide (17 µM) as H3(21-44) peptide lacking any PTMs 
was loaded on the streptavidin coated plates, representing the maximum attainable 
amount of methylation on the histone peptide. The blue horizontal line in Fig. 15 
indicates the methylation level achieved if all of the H3(21-44) peptide substrate used in 
the assay is methylated. 
The cell lysates were initially immunoprecipitated with MIER1 antibody or with 
preimmune serum. The preimmune serum acts as an additional negative control.  The 
methylation assay was performed with cell lysates containing empty vector or MIER1, 
with or without inhibitors (SAH or BIX-01294).  
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As evident in Fig. 15, there was no significant difference between the negative 
control and other conditions when immunoprecipitated with the preimmune serum. 
However, there is significant difference between the negative control and other conditions 
when the cell lysates are immunoprecipitated with MIER1 antibody. There is some 
activity seen in the negative control, which has only empty vector transfected, when 
immunoprecipated with MIER1 antibody. This could be due to endogenous MIER1 
being immunoprecipitated and thus showing methylation activity. However, there is no 
significant difference between the negative control group when immunoprecipated with 
preimmune or with MIER1 antibody. Furthermore, there is no difference between the 
methylation activity of MIER1 without inhibitors or with SAH or BIX-1294. When 
MIER1 complex is immunoprecipated from HEK-293 cells, and subsequently used in 
methylation assay, it has methylation activity towards H3K27. However, the inhibitors 
are not able to inhibit the methyltransferase activity at the concentration used; 200 µM 
SAH, and 17 µM BIX-01294. Higher concentration of inhibitors might be needed to 
inhibit the methylation seen. Optimization of this assay is further needed to determine the 
role of MIER1 complex on H3K27 methylation with certainty.  
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Figure 15: MIER1 complex methylates lysine 27 on H3(21-44) peptide 
Cells were seeded at a density of 5x105 cells /well in 6 well plates and grown in 
DMEM for 24 hr. Cells were then transfected with 0.5 µg pCS3+MT empty vector or 
myc-MIER1 plasmid. Cell extracts were initially immunoprecipitated with either 
preimmune serum or MIER1 antibody and then used in the methylation assay as 
described in Materials and Methods section. The assay was performed using 5µM SAM, 
with and without the inhibitors, 200 µM SAH and 17 µM BIX-01294, with a total 
reaction time of 1 hr at 37°C. Equimolar H3(21-44) K27me2 peptide (17 µM) as the 
unmethylated H3(21-44) peptide was loaded on the streptavidin coated plates which 
represents the maximum amount of methylation that could occur on H2(21-44) peptide. 
This assay was performed in duplicates twice; average of the experiments is depicted in 
the bar graph.  
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Chapter 4: Discussion 
 
4.1   General discussion 
The purpose of this study was to investigate the role of MIER1 and G9a on 
histone methylation of lysine 27 on histone H3 (H3K27). Recently, MIER1 has been 
found to recognise and specially bind to acetylated H3K27 residue (Paterno, unpublished 
data). Our lab has also shown MIER1 to target HDAC’s activity towards H3K27ac. The 
presence of MIER1 augments HDAC activity to remove the acetyl group from H3K27ac 
(Paterno, unpublished data). Since MIER1 has a role in H3K27 deacetylation, in this 
study we investigated the impact of MIER1 on H3K27 methylation.  
In 2008, Mulligan et al. [93] carried out an affinity purification of Flag-HA-
tagged CDYL from HeLa nuclear extracts to isolate CDYL and its associated proteins, in 
an attempt to determine the mechanism and biological function of CDYL. They 
performed a mass spectrometry analysis and identified more than 22 associated proteins 
that copurified with CDYL. These included: HDAC1, HDAC2, G9a, EuHMT1 (G9a-like 
protein, GLP), WIZ (widely interspaced zinc fingers), REST (RE1-binding silencer of 
transcription) and MIER1. Subsequently, they performed a glycerol gradient 
sedimentation analysis to determine whether these proteins form single or discrete 
subcomplexes. From the results, the authors concluded that there are at least two 
multiprotein subcomplexes. One subcomplex contains MIER1/2, HDAC1, and HDAC2, 
while the second slower sedimenting complex includes REST, WIZ, G9a, and GLP. They 
also concluded that the results suggest CDYL and REST and histone methyltransferases 
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to be in the same complex. However, their results show CDYL to be present in both 
sedimentary fractions, with higher amounts in the fraction including the first multiprotein 
complex. Similarly, even though the authors conclude that G9a belongs to the second 
complex, it does overlap with the first complex. Furthermore, MIER1 follows the same 
trend as CDYL, and is present in both multiprotein complexes [93].  
The atrophin family proteins including arginine-glutamic acid dipeptide repeats 
protein (RERE) and Drosophila Atrophin (Atro) are nuclear receptor corepressors which 
share the ELM2 and SANT domains with MIER1 [116]. In 2008, Wang et al. 
demonstrated that both RERE and Atro interact directly with G9a via the SANT domain. 
The authors showed MIER1 to interact with G9a as well [116]. Wang et al., however, did 
not demonstrate which region of MIER1 is responsible for the MIER1-G9a interaction. 
Thus, MIER1-G9a binding was further investigated in my study.  
Initially, a GST pull-down assay using GST-MIER1 constructs and recombinant 
G9a was performed to determine whether MIER1 and G9a interact in vitro. The GST-
MIER1 constructs used were full length MIER1, MIER1 with a three point mutation 
(F326A, Y327A, Y328A) in the SANT domain, and three deletion constructs; GST-
MIER1 construct aa1-283, which contains the ELM2 domain, but lacks the SANT 
domain; GST-MIER1 construct aa287-512, which contains the SANT domain, but lacks 
the ELM2 domain; and GST-MIER1 construct aa287-357, which contains the SANT 
domain with an additional 25 aa downstream of it. GST was used as a negative control.  
The amino acids 326-328 were mutated as they are highly conversed in evolution 
and mutagenesis of these aa leads to changes in the SANT structure [118]. Alignment of 
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MIER1 SANT domain from 9 species, mouse, rat, human, cow, chicken, X. laevis, X. 
tropicalis, zebrafish, and rainbow trout, showed the SANT domain to display 88 % 
identity, with the three aa 326-328 (FYY) to be among the 100 % conserved residues 
[118]. Moreover, the SANT domain contains three -helices which contain highly 
conserved bulky aromatic residues. These aromatic residues form a hydrophobic core 
essential for the overall structural fold of the SANT domain (reviewed in [119]). 
Secondary structure predictions of the MIER1 SANT domain show aa 326-328 to be 
included in the third -helix. Thus, mutagenesis of these aa to alanine would disrupt the 
hydrophobic core of the SANT domain and lead to overall structural alterations.   
The results (Fig. 6) show MIER1 to interact with G9a, and this interaction is 
only evident with the GST-MIER1 constructs containing the SANT domain. GST-
MIER1 construct with the 3 point mutation in the SANT domain interacts with G9a as 
well, suggesting that these amino acid residues do not play a role the MIER1-G9a 
interaction. Moreover, GST by itself interacts with G9a; however, relatively greater 
amounts of GST protein was utilized in the assay. The relatively high amount of GST 
protein could be causing G9a to bind non-specifically. Densitometry measurements of the 
blots were performed for both the amount of G9a binding and the levels of GST-fusion 
constructs used. The amount of G9a binding was then divided by the level of GST 
proteins used and the results were graphed. As evident by Fig. 6B, MIER1 interacts with 
G9a directly. G9a interaction with GST protein is low in comparison to MIER1 (Fig. 
6C). 
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Following the in vitro GST pull down, co-immunoprecipitated between MIER1 
and G9a was performed to elucidate if the two proteins interact and exist in a complex in 
vivo. Initially, HEK-293 cells were transiently transfected with MIER1 and G9a, and 
MIER1 was immunoprecipitated from the cells using MIER1 antibody. The results 
show that MIER1 interacts with full length G9a protein; deletion construct of the protein 
(N-terminal, Ankyrin repeats, SET domain) do not bind to MIER1 (Fig. 7B). 
Subsequently, a reverse co-immunoprecipitation was performed where myc-G9a was 
immunoprecipitated from the cells using 9E10 antibody, and whether MIER1 co-
purifies with G9a was tested. Once again, the results show MIER1 interacts with full 
length G9a protein only (Fig. 7C) [116].   
The GST pull down assay and the co-immunoprecipitation assays show that 
MIER1 interacts with G9a, both in vitro (Fig. 6) and in vivo (Fig. 7). As evident by the 
results, the interaction is direct and it is the region of MIER1 containing the SANT 
domain that is responsible for the binding between the two proteins. GST pull-down 
between G9a and GST-fused MIER1 construct lacking only the SANT domain is 
required to conclude with certainty that MIER1 interacts with G9a via this domain. This 
is consistent with other transcriptional repressors, such as Atro and RERE, which also 
bind G9a by their SANT domain.  
According to Mulligan et al. (2008) [93], G9a, REST and CDYL exist in one 
complex, while MIER1 exists in a complex with HDAC1 and HDAC2. However, as 
shown by our results, MIER1 interacts with G9a, both in vitro and in vivo. Similarly, we 
tested the possibility of CDYL having a role in MIER1-G9a interaction (Fig. 8). Co-
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immunoprecipitation between MIER1, G9a and CDYL (Fig. 8) showed that the 
presence of CDYL did not augment or attenuate the level of G9a interacting with 
MIER1. Similarly, the presence of G9a did not affect the level of CDYL interacting 
with MIER1. This suggests that MIER1 interacts with G9a and CDYL independently 
of each other.  
To further validate the point that CDYL does not have a role in MIER1-G9a 
interaction, CDYL-G9a interaction was tested. Mulligan et al. [93] had tested CDYL, 
REST, and G9a interaction by performing a co-immunoprecipitation. They 
immunoprecipitated REST and checked for the presence of CDYL and G9a. Their results 
indicated that CDYL bridges G9a to REST. They concluded that REST, CDYL and G9a 
are components of the same protein complex [93]. Additionally, they performed a GST 
pull down assay between GST-fused CDYL and flag-tagged G9a and their results showed 
G9a to directly interact with GST-fused CDYL, in vitro. They did not perform any in vivo 
assays to verify this interaction. However, when we immunoprecipitated myc-tagged G9a 
from HEK293 cells, CDYL did not co-purify with it, suggesting that they do not interact 
in vivo (Fig. 9). The levels of flag-tagged CDYL expressed in the cells was low, however, 
it is relatively equal to the co-immunoprecipitated assay between MIER1, G9a and 
CDYL (Fig. 8). In that assay, CDYL interacted with MIER1 strongly despite the low 
CDYL expression level. Mulligan et al. (2008) [93] did not check for the presence of 
MIER1 in the co-immunoprecipitation performed between REST, CDYL, and G9a. As 
evident by the western blot analysis of the glycerol gradient gel assay performed by the 
authors, MIER1 is present in both of the fraction peaks of the two multiprotein 
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subcomplexes. Thus, in their immunoprecipitation assay, it is possible that endogenous 
MIER1 was bridging G9a to CDYL, which in turn bridged G9a to REST.   
In 2011, Zhang et al. [96] showed that CDYL recognizes di- and tri-methylated 
H3K27 and directly interacts with EZH2, which is the methyltransferase component of 
PRC2 complex. Initially, they performed histone binding assays using native calf thymus 
total histones (CTH) as substrates, which demonstrated that recombinant CDYL protein 
mainly interacted with histone H3, but not H4, H2A, or H2B.  To determine whether 
PTMs of H3 have an impact on CDYL-H3 interaction, the authors compared the binding 
affinity of CDYL to native CTHs, which have multiple in vivo modifications, and to 
recombinant Xenopus histone octomers, which lack any PTMs. Their results showed 
CDYL to only interact with native H3 and not with the recombinant H3 octomers. This 
suggested that PTMs of H3 play an important role in the recruitment of CDYL. To further 
verify this, and to determine which PTMs are crucial for this interaction, they performed 
histone-peptide binding assays. Their results showed CDYL to strongly interact with 
H3K9me3, H3K27me2, and H3K27me3 only [96]. H3K27 di- and tri-methylation marks 
are catalyzed by the PRC2 complex member, EZH2. Thus, Zhang et al. (2011) [96] 
examined the in vivo interaction between CDYL and PRC2 by immunoprecipitating 
CDYL from MCF7 cells. Western blot analysis was performed on the immunoprecipitates 
using antibodies against the core components of PRC2. The authors showed that EZH2, 
SUZ12 and EED, which comprise the PRC2 complex, all interact with CDYL in vivo. 
Following the immunoprecipitation assays, the authors performed GST pull-down assays 
between CDYL and the components of PRC2 complex. The GST pull-down assays 
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showed CDYL to directly interact with EZH2 but not EED and SUV12 [96]. They 
concluded that PRC2 is recruited by CDYL in vivo by through interaction with EZH2.  
Recently, two studies have reported EED, a component of PRC2, to bind to 
histone tails with Kme3 PTM by its carboxyl-terminal WD40, and to be responsible for 
H3K27me3 propagation on neighboring histones. Margueron et al. (2009) [120] and Xu 
et al. (2010) [121] showed that EED binds to Kme3 on histone peptides via the top face 
of its -propeller architecture. Three aromatic residues form an aromatic cage which 
accommodates the ammonium group of the Kme3, while a fourth aromatic residue flanks 
the aliphatic chain of Kme3. Their structural data elucidates the preferential recognition 
EED has for the the Ala-Arg-Lys-Ser motif-containing H3K27me3, H3K9me3, and 
H1K26me3 marks over lower methylation states and other histone methyl lysine marks 
[120, 121]. Margueron et al. (2009) [120] also showed that EED binding to histone tails 
with K27me3 marks leads to the allosteric activation of the methyltransferase activity of 
PRC2 complex. Initially, they performed histone lysine methyltransferase (HKMT) 
assays using recombinant oligonucleosomes using unmodified or methylated H3K27 
peptides. Their results showed that using unmodified or mono-methylated H3K27 
peptides as substrates did not affect the enzymatic activity of PRC2 significantly, but tri-
methylated peptides increased its activity by 7 fold. To ascertain whether the observed 
stimulation by the tri-methylated peptides was EED-mediated, the authors used PRC2 
complex containing EED with mutations in the residues forming the aromatic cage (Phe-
97Ala or Tyr-365Ala). These mutations prevent EED from recognising and binding to the 
repressive tri-methylated lysines. When they used the PRC2 complex with mutant EED to 
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perform the HKMT assays, the basal activity was similar to the wild-type, but the 
stimulated activity seen with the addition of H3K27me3 peptides was abolished. 
Moreover, in Drosophila, mutated EED caused a reduction in global methylation and 
disrupts development [120].  Xu et al. (2010) [121] also showed that EED binds to its 
ligands weakly (Kd: 108 μM with H3K27me3) compared to the HP1 chromodomain (Kd: 
4 μM with H3K9me3) and the JMJD2A tudor domains (Kd: 0.4 μM with H3K4me3), 
which suggests that additional chromatin readers might play a role in the recruitment of 
PRC2 complex. The binding affinity of CDYL for H3K27me3 is approximately 20-fold 
higher than that of EED [96]. In addition to binding to H3K27me3, CDYL also 
recognises and binds H3K27me2, while EED does not [96]. Together, these studies 
indicate an additional putative chromatin reader, which connects the unmodified H3K27 
residue to CDYL and subsequently to the PRC2 complex.  
Paterno et al. have shown MIER1 to specifically recognize and bind to H3K27ac 
(unpublished data). MIER1 has also been shown to recruit HDAC [106] and augment its 
deacetylase activity, removing the acetyl group from H3K27 (unpublished data). H3K27 
can be methylated only when it is not acetylated. Thus, MIER1 presents itself as the 
initial chromatin reader, which recruits HDAC to remove the acetyl group and enables 
H3K27 to be methylated by methyltransferases such as EZH2. In previous studies [93, 
122] and ours, MIER1 interacts with CDYL. Additionally, CDYL has been shown to 
interact with EZH2 with higher affinity than EED [96]. Thus, we performed co-
immunoprecipitation using MIER1 antibody and checked whether EZH2 co-purifies 
with MIER1 in the presence or absence of CDYL. This study showed EZH2 to interact 
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with MIER1 only when there is CDYL transfected in the HEK-293 cells alongside 
MIER1 (Fig. 10). This suggests that CDYL acts as a bridging protein between MIER1 
and EZH2.  
EZH2 plays an important role in H3K27 tri-methylation [98, 123, 124]. However, 
the mechanism behind initiation of H3K27 methylation (H3K27 mono- and di-
methylation) is still unclear. We hypothesized G9a to be the enzyme responsible for 
mono- and di-methylation of H3K27. As previously stated, MIER1 specifically 
recognizes and binds to H3K27ac (Paterno, unpublished data). The MIER1 recruits 
HDAC to H3K27ac, augmenting HDAC’s activity towards H3K27ac. The initial 
hypothesis was that once HDAC has removed the acetyl group off H3K27, G9a 
subsequently mono- and di-methylates the lysine residue.  
Initially, we used biotinylated H3(22-44) peptide which contains the lysine 27 
residue as the substrate for the in vitro HMT assays. We used streptavidin-coated plates to 
then capture the biotinylated peptide and used antibodies against H3K27me1 and 
H3K27me2, followed by ELISA substrate, to detect methylation. Our initial experiment 
which used the ELISA approach showed G9a-SET domain to weakly methylate H3K27 
(Fig. 11). However, when we used recombinant histone H3 mononucleosome without any 
PTMs and checked for methylation via western blot analysis, G9a was unable to 
methylate H3K27 (Fig.12). It did however methylate H3K9, a substrate G9a is known to 
methylate with high efficiency. Other studies have shown G9a to weakly mono- and di-
methylate H3K27 [38, 125], but we weren’t able to achieve similar results. 
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In 2001, Tachibana et al. [38] tested the HMTase activity of G9a. They 
demonstrated that G9a is able to methylate H3 at K9 and K27, along with H1 and other 
non-histone proteins. Initially, they used native and recombinant histones to investigate if 
they were a substrate for G9a methylation. Once established that G9a had higher activity 
towards histone H3, they subsequently used GST fusion histone mouse H3 amino 
terminus (residues 1-57) as the substrate for in vitro methylation assays to investigate 
which lysine residue G9a specifically methylates. Their results showed G9a to methylate 
H3K9 and H3K27, with H3K9 being the preferred target site [38]. This is consistent with 
the first methylation assay we performed, using biotinylated H3 peptide containing the 
amino terminus (residues 21-44). SET domain of G9a was weakly able to methylate 
H3K27 on the peptide substrate (Fig. 11). It is only when recombinant histone 3 was used 
as substrate that G9a was unable to methylate K27 (Fig. 12).  A recent study has shown 
wild type G9a to mono-methylate H3K27 in vitro. However, in their in vitro HMTase 
assay they used reconstituted nucleosomes with recombinant histones, free of PTMs 
[125]. These studies suggest that G9a could mono-methylate H3K27, but our data does 
not follow this trend. It is possible that G9a needs the histone substrate to be more 
accessible or be similar to in vivo conditions such as being part of a nucleosome.  
Nuclear receptor SET domain-containing (NSD2) histone methyltransferase has 
different target preferences depending on the nature of the substrate provided. When 
nucleosomes are the substrate, NSD2 mono- and di-methylates H3K36. However, when 
octomers are used as substrate, NSD2 mono- and di-methylates H4K44 [126]. This 
discrepancy in target preference with octomers is diminished when short double-stranded 
or single-stranded DNA is added, which stimulates the NSD2 activity on H3 and 
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inhibitors its activity on H4 [126]. Overall, DNA acts as an allosteric effector of NSD2 
which makes H3K36 to become the preferred target. It is possible that G9a target 
preference varies with the type of substrate or presence of DNA as well, which could 
explain the discrepancy in H3K27 methylation.    
A study done by Rea et al. (2000) [27] demonstrated that the SET-associated 
cysteine rich regions play an important role in methylation as the mutant construct of 
SUV39H1 lacking these regions lacks HMTase activity. Furthermore, the authors 
generated GST fusion products of extended SET domains of human EZH2 
methyltranseferase and human trithorax homolog HRX methyltransferase that correspond 
to GST–SUV1(82–412). Neither EZH2 nor HRX had any detectable HMTase activity 
towards free histones. They also checked the HMTase activity of GST-Suv2(157-477), 
and it was as active as GST-SUV1(82-412) [27]. The C-terminal cysteines are absent in 
EZH2. Similary, the HRX lacks the SET domain-associated, cysteine-rich region. 
Suv39H1 and Suv39H2 have both of these cysteine domains. Together their results 
suggest that HMTase activity towards free histones requires both the SET domain and its 
adjacent cysteine-rich regions.  The G9a protein we used in our in vitro assays is 
comprised of the pre- and post-SET domains containing the adjacent cysteine residues 
and the SET-domain itself. Thus, the enzyme is functional and its activity is evident by its 
ability to methylate H3K9. Nonetheless, G9a is unable to methylate H3K27 in our in vitro 
HMKTase assay.  
It is possible that G9a requires the presence of additional proteins, such as GLP, 
its dimer partner, in order to methylate H3K27. When the methyltransferase activity of 
G9a or GLP is attenuated, mono- and di-methylation of H3K9 is greatly reduced [45].  
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This might apply to H3K27 methylation as well. Furthermore, G9a and GLP are highly 
similar in structure, containing the same domains [46]. MIER1 interacts with G9a (Fig. 6) 
and given the similarities between G9a and GLP, MIER1 could also interact with GLP. 
Moreover, there have been studies which have demonstrated that certain proteins are 
functional or their activity increases significantly when in a complex [98, 124]. For 
example, purified flag- tagged EZH2 protein methylates histone H3, but its activity is at 
least a thousand fold lower than that of the EZH2-EED complex on a chromatin substrate 
[124]. Moreover, purified, flag-tagged EZH2 has four times greater activity on free 
histones than on chromatin. Overall, the difference in specific activity between purified 
flag-tagged EZH2 protein and the EZH2-EED complex on a histone substrate is 
approximately 60-fold [124]. Furthermore, recombinant EZH2 made in Escherichia 
coli or baculovirus-infected SF9 cells lacks HMTase activity [98]. This suggested that 
other members of the complex are needed for the HMTase activity of EZH2 [98], which 
could be the case with G9a.  
This study demonstrated G9a to be in a complex with MIER1 and CDYL, which 
is consistent with other studies [122]. A chemoproteomic profiling study of HDAC 
performed by Bantscheff et al. (2011) [122], using a combination of affinity capture and 
quantitative mass spectrometry, also revealed G9a, GLP, WIZ, CDYL, HDAC1 and 
MIER1 to exist in a complex [122]. Thus, the next step in our study was to examine the 
methylation activity of MIER1 towards H3K27.   
Generally, HKMTs have a catalytic SET-domain which is responsible for adding 
the methyl group on the lysine residues. However, there is a second class of HKMTs that 
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do not possess a SET domain, which is currently only comprised of the evolutionary 
conserved protein DOT1 (disruptor of telomeric silencing, also called kmt4) [127]. 
MIER1 lacks the SET-domain that is present in G9a and other HKMTs, and in this study 
we demonstrated that MIER1 lacks methyltransferase activity (Fig. 14). However, the 
experiment lacked a positive control and thus we cannot conclude with certainty that 
MIER1 lacks methyltransferase activity.  There is a possibility that the methylation 
assay used was not functional. Nonetheless, this study showed the MIER1 complex to 
have methylation activity towards H3K27 (Fig.15). The assay still needs optimization as 
the methyltransferase inhibitor, SAH, which acts by product inhibition, was ineffective. 
Maybe a higher concentration of SAH is required to inhibit the reaction. Development of 
another methylation assay using recombinant histone as the substrate could be used in 
future to confirm the role of MIER1 complex in H3K27 methylation. Overall, our 
results show G9a to have little to no methyltransferase activity towards H3K27. MIER1 
also does not methylate this residue on histone 3.   
4.2   Proposed role of MIER1 in H3K27 methylation 
MIER1 recognizes and binds to H3K27 only when the lysine is acetylated 
(Paterno, unpublished data). Additionally, MIER1 exists in a complex with HDAC1 
[106]. Thus, MIER1 recruits this histone-modifying enzyme, and enables it to remove the 
acetyl group from lysine 27 on H3 (Fig. 16A). Recent findings have shown the presence 
of MIER1 to increase HDAC1 activity significantly (Paterno, unpublished data). By 
removing the acetyl group from the lysine residue, the lysine is now available to be 
methylated by HKMTs. Initially, the hypothesis was that MIER1 would then recruit G9a, 
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which would mono- and di-methylate H3K27. However, this study showed G9a to have 
no detectable methyltransferase activity towards H3K27.  
It is possible that EZH2 is responsible for H3K27 methylation or that G9a needs 
its binding partners to function. In 2006, Schoeftner et al. [128] investigated the role of 
PRC2 in H3K27 mono-methylation. They showed that ES cells deficient in EED also 
lacked EHZ2 and had significantly lower H3K27me2 and H3K27me3 levels compared to 
the controls. However, there was only a moderate reduction in the H3K27me1 levels 
[128]. Montgomery et al. (2005) [129] studied the murine EED, where EEDnull/null cells 
not only had reduced levels of H3K27me2 and H3K27me3, they had significantly lower 
H3K27me1 levels. This decreased H3K27me1 level was rescued in EEDnull/null ES lines 
when they stably expressed low levels of EED, without causing a rescue of EZH2 protein 
levels [129]. This suggests that EZH2 methyltransferase is not required for H3K27 mono-
methylation when EED is expressed. Either EED mono-methylates H3K27 itself (Fig. 
16B) or it recruits another methyltransferase which methylates H3K27. Moreover, 
Suz12−/− embryos, which lack Suz12 and EZH2 but not EED, have significantly reduced 
levels of H3K27me2 and H3K27me3 levels. In these embryos, the levels of H3K27me1 
remain unaffected [130]. This further validates that EZH2 is not essential for H3K27 
mono-methylation. It is possible that a distinct complex which contains or interacts with 
EED mediates mono-methylation of H3K27, and subsequently passes on the role of di- 
and tri-methylation to EZH2.  
Recent studies have shown G9a and GLP to interact with the PRC2 complex in 
vivo [125]. A genome-wide study done by Mozzetta et al. (2014) [125] demonstrated a 
significant overlap between G9a-bound genes and PRC2 target genes. Their results 
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suggest G9a/GLP to cooperate with PRC2 in the regulation of gene expression, especially 
in regulation of a subset of developmental genes involved in neuronal differentiation. 
Moreover, G9a-null, murine embryonic stem cells (mESCs) had impaired EZH2 
recruitment to target genes and H3K27 tri-methylation [125]. This was restored with the 
re-expression of wild-type G9a, but not the inactive form. This suggests that catalytically 
active G9a plays a role in EZH2 recruitment and H3K27 tri-methylation.  
In addition to histone 3, G9a also methylates CDYL [40], and CDYL has been 
shown to interact with PRC2 complex [96]. It is possible that the methylation of CDYL 
enhances its binding to the PRC2 complex. Furthermore, MIER1 could be the mediator 
between these two proteins, enabling G9a to methylate CDYL, which might serve to 
recruit PRC2 complex. MIER1 could be the linker protein between G9a/GLP and PRC2 
complexes, regulating the interplay between H3K9 and H3K27 methylation. The results 
in this study demonstrate the MIER1 complex to have methyltransferase activity towards 
H3K27, and it interacts with EZH2 via CDYL. Therefore, it is possible that MIER1 
recruits G9a and its binding partners such as GLP, and together they are active at 
methylating H3K27 (Fig. 16C).  
Another possibility is that MIER1 could be recruiting another HKMT which is 
responsible for mono- and di-methylation of H3K27. MIER1 then interacts with CDYL 
which recruits EZH2 to tri-methylate the lysine residue. The role of MIER1 in H3K27 
methylation could be that of a regulator, removing acetyl group from lysine 27 and 
enabling mono- and di-methylation by a putative HKMT, and subsequently leading to tri-
methylation by EZH2 (Fig. 16D) and repression of PRC2 regulated genes.  
  
  
Figure 16: Proposed role of MIER1 in H3K27 methylation 
MIER1 is a potential regulator of H3K27 methylation, removing acetyl group 
from lysine 27 and enabling methylation, leading to subsequent repression of PRC2 
regulated genes. A. MIER1 recognizes and binds to acetylated H3K27 (Paterno, 
unpublished data). MIER1 recruits HDAC1 to acetylated H3K27 and enables it to remove 
the acetyl group from H3K27. By removing the acetyl group from the lysine residue, the 
lysine is now available to be methylated by HKMTs. B. EED, a PRC2 member has been 
shown to play a role in H3K27 methylation. It is possible for EED to initiate H3K27 
methylation by mono-methylating the lysine by itself or by recruiting another HKMT. C. 
There is a possibility that G9a-GLP complex di-methylates H3K27 and enables H3K27 
tri-methylation by EZH2. G9a and GLP interact with the PRC2 complex in vivo [128], 
and it is possible that after H3K27 di-methylation, G9a and GLP serve to recruit EZH2 
via its interacting partners. G9a interacts with MIER1, which interacts with CDYL, as 
shown by this study. CDYL interacts with EZH2 [96] and could recruit it to H3K27. D. 
After H3K27 mono- and di-methylation, EZH2 is able to tri-methylate H3K27.  
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4.3   Implications 
Tri-methylation of H3K27 is established by the PRC2 complex and it plays an 
important role in development. The components of the PCR2 complex, EZH2 and EED 
are important in the proliferation of both transformed and non-transformed human cells. 
These two proteins are tightly regulated by the pRB-E2F pathway [131], and deregulation 
of this pathway could lead to tumourgenesis. In accordance with this, EZH2 levels are 
significantly augmented in a large set of human tumours [131]. EZH2 overexpression in 
prostate and breast cancers promotes tumourgenesis and plays a role in invasiveness and 
metastasis [131-133]. Currently, many studies are focusing on development of specific 
EHZ2 inhibitors to block EHZ2 expression or activity. Blocking the downstream 
signaling cascade of EZH2 is a promising strategy for novel anticancer treatment.   
According to my study, MIER1 interacts with CDYL and EZH2, and MIER1 
complex immunoprecipated from HEK-293 cells has methylation activity towards 
H3K27. The HKMT behind the mono- and di-methylation of this residue still remains to 
be verified. However, MIER1 could be the complex responsible for the initiation of 
H3K27 methylation, as it does recruit HDAC, which removes the acetyl group from the 
lysine residue. Only when K27 is not acetylated can it be methylated. Thus, in addition to 
developing inhibitors to alleviate EZH2 expression or activity, MIER1 could be a 
potential target for anticancer treatments. Inhibitors could be developed to diminish 
MIER1’s ability to recognize the acetylated lysine, and thus lowering the capability of 
HDAC to deacetylate the lysine. This will lower the availability of unmodified H3K27, 
and thereby will lower H3K27 methylation. The role of MIER1 in the recruitment of 
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EZH2 should be further studied. If studies show MIER1 to be an important player in the 
recruitment of EZH2, then inhibitors could be designed to target the MIER1-CDYL-
EZH2 interaction. This lowers the accessibility of EZH2 to its target, and subsequently 
will lower H3K27 methylation and repression of the PRC2 target genes. 
4.4   Future studies 
This study examined the interaction between MIER1, G9a, CDYL and EZH2 in 
an attempt to elucidate insights on the mechanism underlying H3K27 methylation. While 
much has been discovered regarding the interaction between these proteins, extensive 
study is needed to determine the role they play in H3K27 methylation. Listed below are 
few experiments that should be completed to further understand the mechanisms behind 
H3K27 methylation.  
4.4.1   Determine in vivo interaction between endogenous MIER1, G9a and CDYL  
 This study demonstrated the in vivo interaction between MIER1 and G9a, 
MIER1 and CDYL, and MIER1, G9a and CDYL by transiently transfecting HEK-293 
cells with MIER1, myc-tagged G9a, and flag-tagged CDYL. Subsequently, the proteins 
were immunoprecipitated and western blot analysis was performed. Even though this 
demonstrated the two proteins interacting in vivo, this required overexpression of both 
proteins in the cell. A better approach in verifying this interaction would be to perform 
immunoprecipitation assays using cells which endogenously express high levels of these 
proteins.  
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4.4.2   Demonstrate in vitro interaction between MIER1 and CDYL 
 The interaction between MIER1 and CDYL in vivo was demonstrated in this 
study, but in vitro interaction remains to be confirmed. Performing in vitro assays such as 
a GST pull-down assay can determine if the interaction between the two proteins is direct 
or requires a bridging protein. If GST pull-down assays confirm the interaction to be 
direct, additional in vitro assays can be performed to determine which domain of MIER1 
and CDYL are involved in the interaction.  
4.4.3   Determine whether MIER1 interacts with other members of PRC2 complex 
 According to this study, MIER1 interacts with the methyltransferase, EZH2, 
which is a component of PRC2 complex, via CDYL. It would be interesting to determine 
whether MIER1 could interact with other members of the PRC2 complex such as EED 
and/or Suv12. If MIER1 does interact with the other PRC2 members in vivo, it could 
further elucidate the role of MIER1 in H3K27 methylation.  
4.4.4   Determine the methylation activity of full length G9a 
In this study we analysed the methylation activity of G9a protein which contained 
only its SET domain with the adjacent pre- and post-SET regions. Even though this SET 
domain was catalytically active towards H3K9, it did not have detectable activity towards 
H3K27. This gives the indication that H3K27 might not be a genuine substrate for 
methylation by G9a. However, to confirm this, the use of full length G9a protein is 
essential, as there is a possibility that other regions and domains of the protein are 
required for H3K27 methylation. Full-length, GST-tagged G9a could be used in the 
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methylation assays performed as we already have the GST-tagged G9a expressing 
plasmid available.  
4.4.5   Determine the methylation activity of MIER1 complex 
In this study, MIER1 was immunoprecipitated from HEK-293 cells and used for 
in vitro methylation assay using ELISA. However, the inhibitors were not effective at the 
concentrations used. For future studies, instead of using histone N-terminal peptides 
[H3(21-44)] as substrate, recombinant histones or nucleosomes should be used to check 
MIER1 complex methylation activity. Currently, the assay is being optimized. Once, it 
is established with proper controls, the methylation potential of MIER1 complex with 
and without CDYL should be compared, as CDYL recruits the H3K27 methyltransferase, 
EZH2. This would give insights on the role of MIER1-CDYL interaction in H3K27 
methylation by EZH2.  
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